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ABSTRACT
Clinical Science Research of the Functional Role of Large Conductance Potassium
Channels in Selective Destruction of Triple Negative Breast Cancer Cells.
Gina Sizemore
The preliminary background that puts this research into context is threefold; it is the aggressive
nature of triple negative breast cancer (TNBC), the complexity surrounding its pathology, and the
significant lack of targeted treatment for this disease. To clarify the focus of my research, I have
concentrated on identifying a targeted treatment for TNBC. In the process, I have identified
cycles of reciprocity between treatment, clinical diagnosis, staging, and pathology that will be
addressed in smaller papers. However, the weight of this work is in the discovery of a novel
target for triple negative breast cancer. The value of this research is evidenced by the significant
discovery of a novel ion channel target that demonstrates selective, targeted destruction of TNBC
without damage to healthy tissue. The specific research aims and objectives are to first,
characterize the big conductance calcium and voltage gated potassium channel (BK) in TNBC to
investigate the apparent contradiction of a depolarized (more positive) resting membrane potential
within the context of a membrane with overexpression of channels that cause hyperpolarization
(more negative) in the membrane potential. Secondly, examine hyperpolarization of TNBC cells
as the mechanism of cell death by severe efflux of potassium
(K) from the TNBC cell via these overexpressed BK channels. Thirdly, establish the first steps
for human translational research of this discovery with evaluation of human TNBC tumor
biopsies for similar overexpression of this BK channel. In summary, the objectives are to fill the
knowledge gap by demonstrating BK channels are not functional (active) in TNBC [which
explains why we can have a positive (depolarized) cell that should be more negative
(hyperpolarized) due to the overexpression of the BK channel but is not]. Secondly, demonstrate
that this overexpression of non-functioning (not-active) channels can be exploited by activating
those channels and hyperpolarizing the cells with efflux of their potassium from the cell as a
mechanism for selective (not impacting healthy cells), targeted treatment for TNBC. Finally,
translating that to a first step evaluation of human TNBC from tumor biopsies.
The additional supportive papers in the scope of this work are in chapter two and chapter four
surrounding the main work in chapter three. The supportive work in chapter two exists to identify
the opportunity for electrophysiology as a tool for translating basic science discovery to clinical
application and is listed as reference [1]. The supportive work in chapter four exposes an
epidemiologic discovery of a translational gap in the clinical diagnosis of triple negative breast
cancer (manuscript under review) where ion channels can impact.

This dissertation interpolates information from the afore mentioned papers by the
author. As described, chapter two references material from reference [1] and was
authored as follows: Gina Sizemore1, Brandon Lucke-Wold2, Charles Rosen2, James W.
Simpkins3, Sanjay Bhatia2, and Dandan Sun4. Chapter three references material from
the main body of work and was authored as follows: Gina Sizemore1, Sarah
McLaughlin2, Mackenzie Newman3, Kathleen Brundage4, Amanda Ammer2, Karen
Martin2, Elena Pugacheva5, James Coad6, Malcolm D. Mattes7, Han-Gang Yu3. Finally,
chapter four supports the research with the transition to epidemiology and references
material authored as follows: Gina Sizemore1, Toni Rudisill2.
In summary, this composition weaves a thread across the clinical translational science
field intertwining chapter two (paper 1) a methods paper of ion channels and the
electrophysiology tool, with chapter three (paper 2) the novel discovery of an ion
channel target, and the epidemiologic opportunity for ion channel translation in chapter
four (paper 3).
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CHAPTER ONE
Introduction

The preliminary background that puts this research into context is threefold; it is the aggressive
nature of triple negative breast cancer (TNBC), the complexity surrounding its pathology, and
the significant lack of targeted treatment for this disease. To clarify the focus of my research, I
have concentrated on identifying a targeted treatment for TNBC. In the process, I have identified
cycles of reciprocity between treatment, clinical diagnosis, staging, and pathology that will be
addressed in smaller papers. However, the weight of this work is in the discovery of a novel
target for triple negative breast cancer. The value of this research is evidenced by the significant
discovery of a novel ion channel target that demonstrates selective, targeted destruction of TNBC
without damage to healthy tissue. The specific research aims and objectives are to first,
characterize the big conductance calcium and voltage gated potassium channel (BK) in TNBC to
investigate the apparent contradiction of a depolarized (more positive) resting membrane
potential within the context of a membrane with overexpression of channels that cause
hyperpolarization (more negative) in the membrane potential. Secondly, examine
hyperpolarization of TNBC cells as the mechanism of cell death by severe efflux of potassium
(K) from the TNBC cell via these overexpressed BK channels. Thirdly, establish the first steps
for human translational research of this discovery with evaluation of human TNBC tumor
biopsies for similar overexpression of this BK channel. In summary, the objectives are to fill the
knowledge gap by demonstrating BK channels are not functional (active) in TNBC [which
explains why we can have a positive (depolarized) cell that should be more negative
(hyperpolarized) due to the overexpression of the BK channel but is not]. Secondly, demonstrate
that this overexpression of non-functioning (not-active) channels can be exploited by activating
1

those channels and hyperpolarizing the cells with efflux of their potassium from the cell as a
mechanism for selective (not impacting healthy cells), targeted treatment for TNBC. Finally,
translating that to a first step evaluation of human TNBC from tumor biopsies.
The additional supportive papers in the scope of this work are in chapter two and chapter four
surrounding the main work in chapter three. The supportive work in chapter two exists to
identify the opportunity for electrophysiology as a tool for translating basic science discovery to
clinical application and is listed as reference [1]. The supportive work in chapter four exposes an
epidemiologic discovery of a translational gap in the clinical diagnosis of triple negative breast
cancer (manuscript under review) where ion channels can impact. This dissertation interpolates
information from the afore mentioned papers by the author. As described, chapter two references
material from reference [1] and was authored as follows: Gina Sizemore1, Brandon LuckeWold2, Charles Rosen2, James W. Simpkins3, Sanjay Bhatia2, and Dandan Sun4. Chapter three
references material from the main body of work and was authored as follows: Gina Sizemore1,
Sarah McLaughlin2, Mackenzie Newman3, Kathleen Brundage4, Amanda Ammer2, Karen
Martin2, Elena Pugacheva5, James Coad6, Malcolm D. Mattes7, Han-Gang Yu3. Finally, chapter
four supports the research with the transition to epidemiology and references material authored
as follows: Gina Sizemore1, Toni Rudisill2.
In summary, this composition weaves a thread across the clinical translational science field
intertwining chapter two (paper 1) a methods paper of ion channels and the electrophysiology
tool, with chapter three (paper 2) the novel discovery of an ion channel target, and the
epidemiologic opportunity for ion channel translation in chapter four (paper 3).
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CHAPTER TWO
Temporal Lobe Epilepsy, Stroke, and Traumatic Brain Injury: Mechanisms of
Hyperpolarized, Depolarized, and Flow-Through Ion Channels Utilized as Tri-Coordinate
Biomarkers of Electrophysiologic Dysfunction

The brain is an integrated network of multiple variables that when compromised create a
diseased state. The neuropathology of temporal lobe epilepsy (TLE), stroke, and traumatic brain
injury (TBI) demonstrate both similarity and complexity that reflects this integrated variability;
TLE with its live human tissue resection provides opportunity for translational science to
demonstrate scale equivalent experimentation between the macroscopic world of clinical disease
and the microscopic world of basic science. The extended value of this research is that the
neuroinflammatory abnormalities that occur throughout astrocytes with hippocampal sclerosis
and damaged or even reversed signaling pathways (inhibition to excitation such as with gabaaminobutyric acid) are similar to those seen in post-stroke and TBI models. In evaluation of the
epilepsy population this interconnectedness of pathology warrants further evaluation with
collaborative efforts. This review summarizes patterns that could shift experimentation closer to
the macro level of humanity, but still represent the micro world of genetics, epigenetics, and
neuro-injury across etiologies of physiologic dysfunction such as TLE, stroke, and TBI with
evaluation of cell function using electrophysiology. In conclusion we demonstrate the
plausibility of electrophysiologic voltage and current measurement of brain tissue by patch
clamp analysis to specify actual electrophysiologic function for comparison to
electroencephalography in order to aid neurologic evaluation. Finally, we discuss the opportunity
with multiscale modeling to display integration of the hyperpolarization cyclic-nucleotide gated
channel, the depolarized calcium channels, and sodium potassium-chloride-one/potassiumchloride-two co-transporter channels as potential mechanisms utilized as tri-coordinate
3

biomarkers with these three forms of neurologic disease at a molecular scale of
electrophysiologic pathology.
Recent statistics indicate 50 million people suffer with epilepsy [1]. In adults with focal epilepsy,
about 50% of them have had a previous brain injury [2]. Approximately 2.3% to 14% of stroke
patients will develop seizures [3] and temporal lobe epilepsy (TLE) develops at rates inconsistent
with heritability alone lending credence to underlying brain damage or otherwise dysfunction as
a contributing feature [4]. A common feature in TLE, stroke, and traumatic brain injury (TBI) is
the electrophysiologic dysfunction. This review will utilize the common thread of electrical
biophysics to identify existing knowledge, expose the gaps, and project a plan for future
research. Although the pathophysiology of epilepsy often begins with the discussion of genetic
mutations, such as the SCN1A gene mutation with over 350 identified mutations [5], those
mutations are not consistent across all epilepsy. For example, a specific mutation in the SCN1A
gene, which affects an alpha1 subunit in the voltage-gated sodium channel, is not compromised
in all epilepsies and not researched at all in diseases like stroke or TBI. Yet, SCN1A has
demonstrated a phenotype associated with hemiplegic migraine [6], which is often a symptom in
TBI. Newer research, at smaller scales, reveals mutations of a variety of genes that encode for
signal transduction, synaptic transmission, neuronal metabolism and excitability, as well as brain
development that play a role in disease pathology. In addition, variability in epigenetics
distributes change that do not alter the original DNA, but create a disease state by alterations like
methylation, and histone modification that can silence or overexpress proteins. Genes can be
evaluated with specificity of their protein expression at the tissue injury region. These epigenetic
contributors are demonstrated across a wide range of epilepsies and show correlation with
encephalopathy seen across the neurophysiological and biophysical mechanisms of blood brain
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barrier compromise in stroke, ion channelopathy of TLE, and white matter apoptosis and
necrosis of TBI. This review builds a plan to pull up from the microscopic and pull down from
the macroscopic to define a place in the middle using a scale of disease evaluation that can be
communicated between the discovery of basic science and the application of clinical medicine.
Despite this wealth of knowledge, greater than 30% of epilepsy patients continue to battle with a
drug resistant seizure disorder while stroke and TBI patients bear the persistent symptoms related
to the electrophysiologic dysfunction that ultimately reflects neurodegenerative change of
varying degrees. Neuropathology of electrophysiologic dysfunction is complex and encompasses
neuro-injury, epigenetics, and genetics. This complexity requires organization of scale to
evaluate the interdependence and integration of these components. The excitability and inhibition
balance required for homeostasis can be compromised by signaling cascades, genetics, or system
failure across multiple neuronal circuits [7]. Therefore, selecting three diverse forms of
electrophysiologic dysfunction: stroke, traumatic brain injury, and temporal lobe epilepsy - this
review will discuss their commonality of electrophysiologic dysfunction, the limitations of the
tools for evaluating electrophysiologic dysfunction, and the benefit of focused analysis with a
hyperpolarized (HCN) channel, a depolarized calcium (CaV) channel and the sodium-potassiumchlorideone/potassium-chloride-two (NKCC1/KCC2) co-transporters. They can be correlated
with the epigenetic expression, RNA and protein analysis to determine biomarkers for improved
evaluation and targeted drug treatment of these diseases.
Translational Research
A challenge in translational research is application of precise, controlled basic science research
to the multi-variable clinical reality. Therefore, evaluation across the three diseases of stroke,
TLE, and TBI demonstrates how electrophysiology offers a broad level translational step
5

between the complexity of the disease (clinical) and the specificity of individual dysfunctional
components (basic science). This review utilizes location, morphology, and neuropathology to
create a context for the discussion.
Location
Circulation to the brain arises from both the internal carotid arteries anteriorly and posteriorly
through the vertebrobasilar artery system [8]. The hippocampus, the focal region of TLE, is fed
through the posterior system with anterior contribution from the anterior choroidal artery.
Although, not the only contributor to translational research shortcomings from mouse to clinic
the vascular diversity requires consideration. The mouse does not evidence the anterior choroidal
artery seen in humans, but with a smaller surface area reflects a more collateral system compared
to the more end arterial system of humans. In Figure 1 you see the comparison of the mouse and
human vascular system. The mouse brain (1A) is created by a novel perfusion technique that
allows resin casting of the mouse vasculature that maintains exact measurements of vascular
diameter and length while eroding all other brain tissue to leave only a model of the vascular
system, no brain tissue. In addition, the casting system maintains the network connections to
demonstrate the collateral system of vasculature in the mouse brain. Everything in the picuture is
vasculature. Compare that to the perfusion of the human brain (1B) in CT scan analysis. The end
arterial system is a striking contrast to the more collateral system seen in the mouse vasculature.
In (1C) the anterior choroidal artery is marked, as it is the only artery reaching to the
hippocampus from the arterial system in humans, apart from the recurrent artery of heubner.
Again, this is contrasted to the more collateral mouse vasculature to the hippocampus, which
may afford it some neuroprotection during injury. It is important to continue animal model
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research. However, it is paramount that research of human tissue at this scale be developed to
offset the limitations of animal models and build on their successes.
Major injury in stroke most frequently occurs from the anterior system, while TBI injury more
frequently involves the posterior system through vertebrobasilar dissection. Therefore, TLE
offers the opportunity of a control disease by virtue of consistent hippocampal location injury for
evaluation with the variant anterior-posterior hippocampal injury from stroke and TBI. The
anterior choroidal artery, a branch off the internal carotid, just distal to the posterior
communicating artery is part of the anterior circulation, which runs deep to the hippocampal
region. In addition, the recurrent artery of heubner originates from the anterior system. The
variation between these two structures is consistent in that when one is dominate the other
balances to a smaller development. The anterior choroidal represents part of the residual
circulation from our evolutionary past before the posterior circulation developed with our higher
cortical brain and therefore along with the heubner artery offers an opportunity to compare and
contrast data with a mouse model in the evaluation of stroke, TBI, and TLE. Though absence of
the anterior choroidal and heubner artery in mice is not the singular cause for the translational
difficulty, research can demonstrate key functional variances between a collateral system
(mouse) and an end artery system (human) in the circulation within a unique vascular region of
brain.
Approximately two-thirds of ischemic stroke arises in the anterior circulation with 90% of those
involving infarct of the MCA [9]. However, despite multiple animal models of MCA injury, we
have failed to discover new drug therapy or targets that translate to successful clinical
application. The anterior choroidal artery, which lies proximal to the MCA and the end artery
structure of humans contrasted to the more collateral structure of mice may offer clues as science
7

develops improved biotechnology to traverse these diverse pathways. In TBI, the most common
vascular injury is subarachnoid haemorrhage [10] with secondary vascular issues from
vasospasm or lumen narrowing of arteries from edema or increased intracranial pressure that
further reduce brain perfusion [11]. Vertebrobasilar dissection is more common than anterior
dissection in traumatic brain injury. The posterior vasculature diameter is narrow and causes
difficulty, even under more stable situations such as bypass grafts where new techniques have
been developed to overcome the disadvantage of these high-flow grafts due to the mismatch in
vessel diameter between donor and recipient vessels in the posterior circulation [12]. With the
hippocampal sensitivity to ischemia dissection in the posterior system leads to decreased
perfusion by both blood loss and arterial narrowing due to acute spasm. The hippocampus is
sensitive to ischemia and periods of excessive intracranial pressure and blood loss could
demonstrate more significant injury in an end arterial human system compared to a more
collateral system. Finally, TLE, which is noted for its hippocampal sclerosis, remains devoid of
significant vascular evaluation despite our knowledge of glial cell function in maintenance of the
blood brain barrier and its dysfunction in developing sclerosis. The brain vasculature represents
the pathway in and out of the neurologic circuitry and is too broad to cover the entire network for
all three diseases. Therefore, location will be restricted to the vascular distribution of the
hippocampus which reaches deep into our evolutionary past, yet still offers parameters with
defined limits for the discussion of stroke, TBI, and TLE within a framework that makes them
consistent with one another by virtue of location. In addition, it addresses specific gaps in our
knowledge of glial involved vascular injury in TLE, hippocampal role in cognitive and memory
decline in TBI, and isolates a specific region for analysis of core versus penumbra injury in
stroke. “The penumbra is characterized by the loss of action potential firing but maintenance of
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proper resting membrane potential” [13]. Resting membrane potential and action potential firing
are key electrophysiologic targets translational research can utilize.
Electrophysiology
Neuroimaging is the gold standard evaluation in stroke and TBI and offers benefit in surgical
planning with TLE. However, despite the benefits of these tools, they fail to establish data that
connects structural abnormality and electrophysiologic dysfunction in the brain that translates to
improved clinical outcomes [14]. EEG provides cortical activity markers in real-time [15] which
augment the time lag in neuroimaging. However, few facilities have compatible tools to perform
these tests synchronisly and have led to decreased use of electrophysiologic tools in preference to
BOLD MRI, perfusion CT, and specialized manipulations of scans as accessories to primary
MRI and CT for many neurologic diseases. Therefore, assessment of neuronal oscillations with
electroencephalography and ion channel function is a novel way to assess the balance between
excitatory and inhibitory cortical processes and provide biomarkers for future evaluation and
treatment. The HCN1 channel, the CaV channel, and the NKCC1/KCC2 cotransporter channels
are representatives of hyperpolarization, depolarization, and flow through that can create a threeprong coordinate evaluation of current that can be used as a biomarker to aid evaluation and
treatment being done with neuroimaging and electrophysiology tools such as EEG. In addition, it
reflects the opportunity for bioengineering to develop alongside new electrophysiologic
technologies such as microelectrode arrays, which improve spatial resolution over EEG. These
data can be correlated with data from electrophysiology (See Figure 2). The glass pipette
patching an astrocyte (2C) indicates the opportunity electrophysiology offers to bring the
macroscopic world (2A) the glass pipette electrode and (2B) the microscopic world of an
astrocyte together and produce (2D) research data in real time electric current evidence of cell
9

function that communicates with a language that is the same in the macroscopic and microscopic
world. Thus, creating the possibility to translate information between scales of the very small and
precise (basic science discovery) and scales of the very large and complex (clinical application).
Morphology
Morphology evaluation is based on literature, which demonstrated large-scale involvement of
astrocytes and pyramidal neurons in all three diseases. Astrocytes are an active and reactive
component of the brain that influences gene expression, extracellular matrix components, and
metabolism. When injured they display distinct features compared to healthy astroglia in their
morphology, expansion, and signaling in ischemia [16] as well as TBI [17], and sclerosis in TLE
[18]. Pyramidal neurons are the most common recipient within the environment of change
commanded by astrocytes. Specific cell types vary by location which ultimately effects their
function within those regions and the hippocampus remains a controversial region [19]. In
addition, ion channel distribution on any given cell differs and contributes variation to the cell
function. The pyramidal neurons of the CA1 region of the hippocampus are extremely sensitive
to ischemia and ion channel research continues to evaluate this for mechanism though it is not
yet well defined [20]. Unlike the L5 pyramidal neurons, which stretch through all five levels of
the cortex, the CA1 pyramidal neuron structures remain confined to the CA1 hippocampal region
and offer a specific region for discussion and experiment to isolate changes affected by stroke,
TBI, and TLE. The diversity of cell structure contributes to the variety of function each cell
offers to the brain (See Figure 3). It demonstrates the variance of a pyramidal neuron (3A);
notice the CA1 and CA3 pyramidal neurons, of specific interest within the hippocampus,
compared to the Layer V(LV) pyramidal neuron. In (3B) the LV pyramidal neuron with its
streamline look reaches through all six layers of the neocortex, with little to no branching, while
10

the more compact CA1 and CA3 of the hippocampus with their apical branching are designed for
their local purpose. Research indicates a large percentage of HCN channels are expressed in the
apical region of pyramidal neurons. The benefit of whole cell patch is it reads the resting
membrane potential of the entire cell at the soma (3C). The alternate protocols available in whole
cell patch, such as Ramp protocol (3D) and Pulse protocol (3E) allow evaluation of specific
electrical changes in the entire cell. Therefore, the hippocampus, with the apical girth of CA1
and CA3 offers opportunity for significant evaluation with electrophysiology of these
hyperpolarized channels in epilepsy and other neurologic disease.
Genetic and epigenetic modifications play a role in the channel construction, and expression of
the channels discussed in this review. Within the spectrum of each disease the full context of
those modifications is not yet understood. This review’s purpose is to demonstrate the pathology
based on the role of the channels within the cell for depolarization, hyperpolarization, and flow
through or electroneutral current to open further discussion of experiment direction for disease
specific research evaluating these channels as coupling or co-contributing channels in multiple
disease pathology. HCN as a hyperpolarizing channel leads to hyperexcitability when it is
mutated from its normal function, Ca leads to multiple variations of depolarization and
intracellular activity when it mutates from its normal function, and the electroneutral cotransport
channels already demonstrated as coupling with sodium and potassium alter their flow-through
neutral status when they mutate from normal function. Approaching this from a predominantly
electrophysiologic perspective puts focus on the function of the channels when they are mutated
or have variant expression more than on the depth of discussion of each mutant variation. A
mutation either causes the channel to work more effectively, less effectively, or not at all.
Overexpression or underexpression similarly may impact function but, may also not affect cell
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function at all. This review aims to discuss the role of these channels in the broader terms of cell
function in the context of disease rather than specific mutations for any gene family.
Figure 3D Demonstrates a Ramp protocol, which is the simplest screening tool to evaluate
channels that open with depolarization. We have used this protocol in research to demonstrate
how overexpression does not always tell you what the function will be in the cell. If there is
overexpression of a specific channel on a scale of 1000 to 1, yet only 5% of channels are open at
the physiologic state then having overexpression of essentially 1000 doors does not matter. The
function in the cell does not change if they are not open. Therefore, electrophysiology can give
us functional data about what is going on in the cell without being distracted by genetic
mutations that may pose no effect to the function or dysfunction of the cell in the disease. Yet
equally, when there is abnormal function in the cell researchers can track that dysfunction back
to its specific components of mutation and expression.
Neuroinflammation
The signaling pathways for neuroinflammatory response have been exposed as a contributor to
pathology in neuro trauma, whether the acute injury of stroke, TBI, or the chronic sclerosis of
TLE. Research linked NKCC1 signal increase to increased ischemic risk [22]. Inflammation of
astrocytes, seen in temporal lobe epilepsy, occurs due to excess glutamate through the
glutamine/glutamate/cycle (GGC) [18]. There is significant change demonstrated in the pathway
from epileptogenesis through sclerosis in a hippocampal astrocyte cell. Comparable astrocyte
damage occurs in post-stroke by compromise of the arteries where astrocytes assist in
maintaining the blood-brain barrier and in TBI with similar compromise of the blood-brain
barrier where in mouse models it is associated with memory changes [23]. There is glutamate
uptake at the astrocyte where it is converted by glutamine synthetase to glutamine and released
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to the extracellular space. The neuron then uptakes the glutamine where it is degraded to
glutamate by phosphate activated glutaminase (PAG) and released back to the extracellular space
as glutamate to continue the cycle. There are multiple opportunities for the system to fail in this
cycle from glutamine synthetase deficiency or glial glutamate (GLT-1) transporter dysfunction in
the astrocyte to neuron dysfunction by excessive release due to (PAG) and the excitatory amino
acid carrier (EAAC1); all of which contribute to extracellular/intracellular ion gradient shifts that
disrupt homeostasis.
Neurodegeneration
Neurodegeneration is a natural path from the epigenetic contributions of neuroinflammation. The
degeneration of neural tissue in neurologic disease is not singular in its origin and due to mixed
contributions of neuroinflammation, gene expression, and ion dysregulation it is difficult to
determine the cause and direction of pathology [24]. The epigenetic impact of the inflammatory
process can create signal error or excess that leads to sclerosis and/or blood brain barrier breach
[25]; just to name a few. New research indicates mitochondrial mechanism with miR-34
mediated regulation of the blood brain barrier and analysis with bioinformatics indicates several
gene targets [26]. Research correlating upregulation and down regulation of co-transporter
channels such as NKCC1 and KCC2 respectively following injury [27] support research of these
channels in the pathology of stroke, TLE, and TBI where neuro inflammatory processes led to
neurodegeneration. In addition, inflammation can produce neurodegeneration by abnormal gene
expression, trigger regulating error, and channel surface expression variation with posttranslational modification. For example, the HCN1 channel has an exposed extracellular
posttranslational modification where circulating inflammatory signals may contribute to
dysfunction. Further review of a susceptible post-translational modification site exposed on the
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HCN1 channel can be found in Lee et al., 2017 [28]. These epigenetic influences of
neuroinflammation can diverge from neurodegeneration and impact neurogenesis as well.
Neurogenesis
Increased ion channel density demonstrated significantly depolarized astrocyte cells in
hippocampal foci damaged regions (~55 mV) compared with astrocytes in hippocampal
neurotypical regions (~75 mV) since early channel research [29]. This channel density
neurogenesis continues in recent research, most notably in new research regarding NKCC1 and
KCC2 co-transporters where ratio shifts to embryologic conditions indicate again the role of
channel density in the probability for dysfunction [30]. In addition, the electrophysiologic effect
of channel density on surface expression, post-translational modification, and signaling
demonstrate the interconnectedness and circular difficulty of the pathology. The anticipated
voltages can be calculated by Nernst equation demonstrating the polarity shift that the ratio
inversion of NKCC1 to KCC2 could create in the membrane potential (see Figure 4). The Nernst
equation in figure four demonstrates the role that concentration of a single ion can play in
altering the membrane potential of a cell. With so many basic science variables from gene
expression to neuroinflammation, neurodegeneration, and neurogenesis it is necessary to find a
system that reflects the function of them all. Electrophysiology can extract the functional data
that in turn can be correlated with microscopic science and macroscopic disease.
Ion Channel Milieu
Regulation of ion homeostasis is critical to the function of cells. Ion transporters establish that by
cell volume, voltage influence of membrane potential, and signal transduction [31]. Shifts in
cellular volume and gradient pressures trigger homeostatic responses coordinated by ion
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channels to mediate and avoid excessive cellular edema or dehydration with regulatory volume
adjustments [32]. Membrane potential is primary in the discussion of cell survival and function.
Therefore, membrane potential is the necessary starting point. The HCN1 channel with its Ih
funny current displays a reversed polarity in its biophysical nature with a reversal potential ~ −20
mV carrying a cation current of both Na+ and K+ that is inward moving at rest [33]. This
combination along with additional features to be discussed creates an intersection of opportunity
for interaction with sodium-potassium-chloride cotransporters NKCC1/KCC2. Signal
transduction pathology disrupts cell homeostasis. It is here where ion channels can create
significant influence. GABA is one of the most researched contributors to signaling pathways
and demonstrates the importance of ion channel interaction in the discussion of negatively
charged ion concentrations, such as Cl- within the cell membrane [34].
Hyperpolarized Cyclic-Nucleotide Ion Channels
Sequencing, Construction, and Function
HCN role in epilepsy is a function of its isoform’s homomeric or heteromeric channel
construction, expression, and interaction. There are four HCN isoforms: HCN1, HCN2, HCN3,
HCN4. The expression of HCN1 is more prevalent in the hippocampus and cortex compared
with the HCN2, and HCN4 isoforms, which are more prominent in the thalamus and sinoatrial
node [35]. In discussing the role of HCN channels in epilepsy it is not a singular mutation of the
channel but rather a combination of channel construction variance as well as altered expression
which demonstrated epileptic disease in mouse models [35]. In addition, deletion of HCN1 and
HCN2 in knock-out mice created seizure prone mice [36].
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However, the structure of the HCN1 channel is showing significant promise for integrated roles
with its reversed polarity [37]. The hyperpolarization as opposed to depolarization gating make
the HCN1 channel an excellent candidate for integrated research with NKCC1 and KCC2 cotransporter channels along with the depolarization gating of the high voltagegated CaV channels.
The construction of the HCN1 channel pore has great conservation with that of the K+ channels;
both contain the glycine-tyrosine-glycine (GYG) as a selectivity filter [38]. The function of the
HCN1 channel is to operate with reverse polarity and it does this by structural design that allows
for conformational changes of the pore based on the trigger mechanism. Using cryo-electron
microscopy (Cryo-EM), researchers demonstrated the alternated gating between
hyperpolarization and cAMP modulation [37]. We hypothesize that hyperpolarization channels
like HCN1 in conjunction with inappropriate NKCC1/KCC2 co-transport channel ratios allows
function gain or inhibition at a more negative membrane potential leading to hyperexcitation,
epileptogenesis, neuroinflammation and therefore has a high potential link to hippocampal
astrocytic and pyramidal neuron injury with evidence of electrophysiologic dysfunction either as
neurodegeneration, hyperexcitation or both in stroke, TBI, and TLE. HCN produces a current
called funny current, If , in the heart and is considered the pacemaker current. It is often written
as Ih when discussing its current in the brain. The Ih current is an inward current [39]. Its
complexity of construction from homomeric to heteromeric, as well as expression of the channel,
impacts how closely to resting cell membrane potential the channel can be triggered.
Additionally, reduction in expression as well as complete deletion such as is done in knockout
mice consistently indicates increased seizure risks and activity in other neurologic disease such
as stroke and TBI.
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Channel electrophysiology connects with epilepsy, stroke, and traumatic brain injury by offering
a context of functional evaluation to these diseases. Each disease has pathology rooted in failing
cellular processes of which ion channels are a key component. When using an evaluation of scale
as macroscopic as a complete human disease it is difficult to correlate it with equal scale at the
basic science level (i.e. discuss the function of a cell, as a whole, rather than a single variable of
change such as a histone modification that changes the expression of a gene). Each of these
individual discoveries is important. However, electrophysiology of cell function creates a closer
equality of scale for translational science because the microscopic data is measured, discussed,
and analyzed with the same tools as the macroscopic data. Resting membrane potential,
depolarization, and hyperpolarization states are mandatory tools for a cell’s homeostatic balance.
In this review we press for the whole homeostatic electrical balance system of the cell to be used
for representation of the larger scale human disease. It is not equivalent, but it is a starting point
to begin the translational discourse between clinical and basic science. Ion channels play a role in
the diverse signaling throughout stroke injury at glial cells, neurons, and the blood brain barrier
[40]. Traumatic brain injury leads to variant excitotoxicity, which could be evaluated, with
electrophysiology to better understand the functional changes at the cellular level [41]. Epilepsy
results in hyperexcitability recorded by electroencephalography and confirmed in
electrophysiology recording baths at the cellular level by evaluation of ion channel function [42].
Experimentation to evaluate these diseases for similarities with channels specific for these
electrical potentials can establish a baseline for deeper discovery of the disease process.
Electrophysiology is the translational lane of research that is yet to be completely developed and
explored; a lane that runs like a blood brain barrier between the worlds of clinical research and
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basic science (See Table 1). This electrophysiologic diversity can be evaluated further with
future research since evidence for all four HCN isoforms in the brain have been described [43].
NKCC1 and KCC2 Co-Transporter Ion Channels
Sequence, Construction, and Function
Research on variants have associated R952H and R1049C of the KCC2 co-transporter channel
with idiopathic generalized epilepsy (IGE) [45] a more generalized epilepsy. KCC2 plays a
dominant role in normal development, influencing factors such as the excitatoryinhibitory signal
read of GABA [46]. When KCC2 is deficient, especially in relevance to NKCC1, brain
development is compromised. Intracellular chloride currents show biophysical accumulation
when the ratio construction of NKCC1 expression is higher compared to KCC2 expression [47].
This leads to severe neurologic dysfunction and delay noted due to decreased function of the
NKCC1/KCC2 co-transporter’s ability to maintain low intracellular Cl- because of mutations at
SLC12A5 [48]. The fundamental role of Na-KCl cotransporter 1 (NKCC1) and K-Cl
cotransporter 2 (KCC2) is lost when the expression of each is not regulated properly. In addition,
the integrated signaling system as it relates to GABA is disrupted [49]. The NKCC1 and KCC2
provide the Cl- homeostasis voltage within the cell [50], which is why they are pertinent to
evaluation of hyperpolarization-gated channels like HCN1.
The deregulation of NKCC1 in epilepsy is demonstrated by the increased association with
epileptogenesis due to its role in managing the concentration of intracellular chloride [51]. The
slc12 gene family encodes both NKCC1 and KCC2 and mutations in this gene have been
associated with epilepsy. Many of these electroneutral chloride cotransporters functionally
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couple movement of chloride with Sodium and potassium and have demonstrated pathological
hyperexcitability in mice with genetic modifications of this gene [52].
In models of evaluation these chloride channels demonstrate the detrimental effect of neuroinjury
on their ratios to one another. Multiple research platforms including ischemic stroke, TLE, and
subarachnoid hemorrhage (the most common brain injury in TBI) reveal the correlated role
between disease and damage in these channels. Western blot analysis by Yong Tien, et al (2015)
revealed multiple neuroinflammatory components following subarachnoid hemorrhage. The
NKCC1 and KCC2 ratio shifts were significant, demonstrating changes of their protein
expression [53]. Western blot analysis characterized a decline in KCC2 expression and increase
expression in NKCC1 following induced subarachnoid hemorrhage in their rat model.
Topiramate, a frequently used anticonvulsant, effectively reversed those KCC2/NKCC1
expressions in a dose-dependent fashion. This response is a positive indicator of pharmacologic
opportunity as we learn more about the integration of these channel functions.
High Voltage-Gated Calcium Ion Channels
High voltage-gated calcium ion channels are discussed briefly below due to their connections to
epilepsy and the role they could play in the development of an integrated computational model of
ion function for future research.
HVA calcium channels have five known types, all derived with an original subunit: CaV1 the Ltype, CaV2 including the P/Q-type [CaV2.1] the R-type [CaV2.2] and N-type [CaV2.3], and the
CaV3 the T-type. These types have been studied with regards to genome structure, mutation,
pathology, and pharmacology. The results thus far are promising. The P/Q type is the CaV2.1
type of the five types and has the most connection with epilepsy along with the CaV3.2 T-type.
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They both are linked to IGE. The HVA channel requires higher depolarization, compared to
LVA channels. Yet, both are linked to IGE, both are pharmacologically responsive, and have
improved epilepsy outcomes with inhibition in patients [54]. Low Voltage Gated Channels like
the T-type channels offer the first glimpse of opportunity for hyperpolarized channels and
negative charge transporters to be linked to IGE. The structural changes and pathology of these
channels is tied to congenital mutations associated with IGE which raises the question for
susceptibility to more epigenetic, neuroinflammatory changes linked with more focal epilepsy
like TLE, post-stroke epilepsy (PSE), and post-traumatic epilepsy (PTE). The voltage-gated
channels have many polymorphisms that contribute to the mutations leading to structural and
functional change [55], but alone they do not answer all the questions regarding
electrophysiologic dysfunction.
The CaV families, which are the L-type channels [CaV1], P/Q-type [CaV2.1] (R-type and Ntype of CaV2 family not reviewed here), and T-type [CaV3] channels, have defined structure.
The CaV1 and CaV2 types have an alpha subunit that forms the pore of the channel and a
gamma, beta, and alpha2delta unit forming the tertiary structure. These channels are closely
related to the CaV3 channel, which also has an alpha unit pore [56]. Splicing variants of each
subunit contribute to altered phenotypes associated with epilepsy [57]. These splice variants
determine biophysical properties and tissue location of channels [58].
Current data from both animal models and clinical trials point to CaV2 the P/Q type HVA
channel, and the CaV3 T-type LVA channel as important, but not alone in their epileptogenesis
role. These channels are well studied and presented briefly here due to their strong link to IGE
that could shed light on the genetic contributions to the electropyysiologic dysfunction of TLE,
stroke, and TBI. In addition, the role of calcium in contributing to glutamate excitotoxicity is
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relevant [38]. Whether from ischemia, TBI, or epilepsy the rich research database on HVA
calcium channels can help form a background for baseline computational modeling regarding ion
gradients.
Clinical Relevance and Conclusion
The animal models for stroke, TBI, and TLE are beneficial to science and humanity in our
growth of knowledge, yet they often fail to translate to improved outcomes in human clinical
applications. Animal models have demonstrated multiple failures in producing drugs with safety
and efficacy in humans despite success in preclinical experiments [59]. What are the limitations
that contribute to this discrepancy in translation from bench science to clinic?
Limitations of Electrophysiologic Tools
Unlike Electrocardiograms (ECG/EKG), which are standard of care in heart attack evaluations;
stroke, with its similarities of ischemia, rarely receives evaluation by an electroencephalogram
(EEG) until the following day, if at all. EEG gives an electrical reflection of the brain’s activity.
In focal epilepsy, such as TLE, that can be focal waves or spikes [60]. In addition, electrical
abnormalities consistent with encephalopathy are often seen in stroke patients when EEG is
performed. Yet, many rural hospitals do not utilize EEG to monitor patients with these
neurologic conditions because of limitations in skilled personnel and of the equipment itself.
Whether evaluation is in a mouse model or a hospital, the spatial discernment sacrificed by
electroencephalography due to the bony scalp and other confounding obstacles between the
electrodes and the signal cannot always be overcome by the timing integrity of the machine.
Event related potentials, frequency spectrum analysis, and other mechanisms of analysis assist in
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overcoming these limitations [15]. However, training and validation of the researcher’s
technique can consume large amounts of research time.
Overcoming EEG Limitations
Microelectrode arrays and local field potentials show promise in the prediction and localization
of preictal activity prior to seizures in TLE [61]. As these tools develop new limitations emerge.
For example, a micogrid covers a large surface area in a mouse, but in a human in is a very small
area for analysis. This is where the growth of molecular biology and electropyhsiology targets
the analysis of these small areas with the precision of basic science. With these developing
technologies, the opportunity for molecular biology to create biomarkers of electrophysiologic
dysfunction in diseases such as TLE, stroke, and TBI is present and could prove to be the
translation required to bring bench science more effectively to the clinic.
Pharmaceutical Limitations
Anticonvulsant pharmaceutical products create the first line of defense for clinicians treating
patients with epilepsy. However, many of the medications are non-linear in their kinetics which
means their half-life and clearance are dependent upon plasma concentrations which can
fluctuate, reducing the ability to maintain steady state of the drug. In addition, anticonvulsants
such as Valproic acid, and Clonazepam are greater than 88% protein bound so they do not cross
the blood brain barrier well and therefore provide little if any medication to the targeted areas. In
addition, Valproic acid and similar drugs demonstrate serum protein saturable binding which can
impact other medications when given simultaneously [62]. Newer anticonvulsants such as
ethosuximide and topirimate are more promising, yet the disease is far from controlled. Stroke
pharmaceutical options are more limited in that after decades of research we have essentially one
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medication; tissue plasminogen activator (tPA) that can be used in stroke and that is limited to
specific time frames, and patient types. Finally, in TBI there are multiple complicating factors
with medication management due to the complexity of symptoms from post-traumatic stress
disorder to epilepsy.
Therefore, improved target evaluation and treatment based on a demonstrated abnormality of
electrophysiologic dysfunction offers a significant opportunity to identify biomarkers for
bioengineering and innovative technologies for multiple neurologic diseases.
Ion Channel Options
Ion channel targeting offers unchartered opportunity for further evaluation and treatment for
TLE, stroke and TBI. Research demonstrates the adaptation of neurons across cellular types[63].
The integration of channel structure and function with cellular stability is described and accepted
across research fields, though all the intricacies of how that works are not yet understood.
Continuing the process of collaborative research evaluating the interactions and correlations of
multiple variables from genetics to inflammatory response by precise research of atomic
chemistry at the ion channel level can expose those unknowns at the molecular level. In addition,
the collaboration of scientists and technology can compile research data that can be integrated at
unprecedented speeds and with increased safety. The Department of Defense, National Institutes
of Health (NIH), and other large organizations recognize the increasing need for better outcomes
for patients suffering with neurologic diseases like TBI, stroke, and TLE. NIH published a notice
in the NIH guide in 2011 encouraging the scientific community to address the issues of
predictive failure in preclinical research [64]. The focus to bring basic science to the bedside
more efficiently, safely, and effectively creates an opportunity for research that can begin at this
primary level and build forward. Evaluating the process of interaction between hyperpolarized
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HCN1 channels with its unique polarity, depolarized calcium channels, and NKCC1/ KCC2 ratio
shifts in neuropathology creates a single variable of interaction that can be modeled in a multiscale modeling system with a designed control of homeostasis juxtaposed to the actual cellular
expression identified by genetic analysis of diseased human tissue. The single constant of a
homeostatic model that is computerized and easily modified as new data arrives lends itself not
only to comparison against disease tissue, but also better understanding of homeostasis as we
start to define the variation within normal. It is against this contrast that we will bridge the gap
from bench to bedside and create - in real time - questions that can be answered safely and with
better precision before heading to animal and clinical labs for experimentation. This can reduce
the time to successful treatment in clinical application and increase efficacy and safety as we
identify potential mechanisms that lead to neurodegenerative changes. TLE hippocampal
sclerosis, ischemia in stroke, and blood brain barrier compromise in TBI can establish a baseline
evaluation of electrophysiologic dysfunction. Then interaction and interdependence of the HCN1
channel, CaV channel and the NKCC1/KCC2 co-transporter channel can correlate dysfunction
with structure.
Building A Mouse Model
Location/Vascular —A global stroke model in mice creates hippocampal ischemia by way of
the posterior circulation consistent with cardiac arrest as well as stroke. Mice have more
collateral vascular systems unlike the end artery system in humans and the divergence of humans
from that evolutionary past may hold one of the keys to improved biomarker targeting for
humans. Therefore, comparison of the mouse model hippocampal data to human supplemental
data can expose mechanisms for translational failures of mouse stroke models to clinical
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application and open doors for other neurologic disease discussion such as epilepsy and TBI as
discussed below.
Morphology – Pyramidal neurons and astrocyte immunohistochemistry evaluation within the
hippocampus can be used to demonstrate where - on the cellular structures - inclusion of HCN1
channels in control, ischemic injury mice, and hemorrhagic injury mice occurs. Further
immunohistochemistry evaluation of mice from control, ischemia, and hemorrhagic stroke
groups, triggered to seizure with kainic acid, can be analyzed for HCN1 channel expression prior
to and after seizure. This further characterizes location and identifies spatial relationships for
comparison to later human research. HCN1 channels with their extracellular exposed posttranslational modification tail may demonstrate significant changes and prove a key biomarker to
stabilize the first coordinate of a tricoordinate system.
Structure – mRNA sequencing and Western blot for protein expression of HCN1 will reveal
increased or decreased expression changes in hippocampal regions exposed to specific injury.
Function – Acute fresh tissue for electrophysiologic evaluation with specific voltage data by
patch clamp on dissected hippocampal tissue can then deliver functional data to correlate with
specific structure, morphologic, and anatomical data. This precision analysis creates the
foundation for a model of translational human tissue analysis.
Supplemental Future Research
Human Research
Electrophysiology State of the Art Technique – IRB approved human research that can safely
evaluate human tissue electrophysiologicaly from initial injury (EEG), through craniotomy and
intraoperative electrophysiologic monitoring (intraoperative EEG) during tissue resection.
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Discarded tissue can then be evaluated for its voltage and current by patch clamp analysis to
specify actual electrophysiologic function for comparison to macro tool evaluation. That
electrophysiologic data can then be connected with the structural expression of biomarker
channels demonstrated in spatial localization by immunohistochemistry and total expression of
mRNA and protein by RT-PCR and western blot.
Building the Future
Multi-scale Modeling – Data programmed from the evaluation of the HCN1 hyperpolarizing
channel, and additional channels such as the depolarizing calcium channels, and the flow through
NKCC1/KCC2 co-transporter channels to demonstrate what is seen experimentally. This
programmable data can then be used in simulations of tri-coordinate biomarkers for targeted cell
therapy as a translational tool for future experiments prior to clinical application trials.
Summary
In summary, this reflects the limitations and difficulties of translation between the microscopic
bench science and the macroscopic world of clinical disease. The need for clinical translational
science evidenced by the 17-year delay between bench and bedside1 is more evident than ever.
Electrophysiology offers that translation because it communicates across measures of scale.
Depolarization in the cell’s resting membrane potential is represented the same way as
depolarization on an EEG or EKG. It is this connection of depolarization that will be discussed
in the next chapter both at the microscopic level of basic science and at the macroscopic level of
disease. In chapter three you will see electrophysiology bridge the translational gap when a
microscopic ion channel proves to be an electrophysiologic target for treatment of a deadly
macroscopic clinical disease called triple negative breast cancer.
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CHAPTER THREE
Opening Large-Conductance Potassium Channels Selectively Induced Cell Death of TripleNegative Breast Cancer

Background: Unlike other breast cancer subtypes that may be treated with a variety of hormonal
or targeted therapies, there is a need to identify new, effective targets for triple-negative breast
cancer (TNBC). It has recently been recognized that membrane potential is depolarized in breast
cancer cells. The primary objective of the study is to explore whether hyperpolarization induced
by opening potassium channels may provide a new strategy for treatment of TNBC.
Methods: Breast cancer datasets in cBioPortal for cancer genomics was used to search for ion
channel gene expression. Immunoblots and immunohistochemistry were used for protein
expression in culture cells and in the patient tissues. Electrophysiological patch clamp techniques
were used to study properties of BK channels in culture cells. Flow cytometry and fluorescence
microscope were used for cell viability and cell cycle studies. Ultrasound imaging was used to
study xenograft in female NSG mice.
Results: In large datasets of breast cancer patients, we identified a gene, KCNMA1 (encoding for
a voltage- and calcium-dependent large-conductance potassium channel, called BK channel),
overexpressed in triple-negative breast cancer patients. Although overexpressed, 99% of channels
are closed in TNBC cells. Opening BK channels hyperpolarized membrane potential, which
induced cell cycle arrest in G2 phase and apoptosis via caspase-3 activation. In a TNBC cell
induced xenograft model, treatment with a BK channel opener significantly slowed tumor growth
without cardiac toxicity.
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Conclusions: Our results support the idea that hyperpolarization induced by opening BK channel
in TNBC cells can become a new strategy for development of a targeted therapy in TNBC.
Background
The main molecular subtypes of breast cancer are termed Luminal A (ER+/HER2-),
Luminal B (ER+/HER2+/-, higher histological grade, more aggressive than Luminal A), HER2enriched (ER-/HER2+), and triple-negative (ER-/PR-/HER2-) [1]. Recent gene expression studies
further identified five “transcriptional subtypes” of breast cancer: basal-like, HER2-enriched,
luminal A, luminal B, and normal-like (now thought not to originate from breast cancer) [2]. Up
to 70% of triple-negative breast cancer (TNBC) have the basal-like gene expression signatures,
however, a large number of basal-like tumors express ER, PR or HER2 [3]. Further studies on
molecular signatures, genetics, and genomics have led to the identification of four TNBC subtypes
(basal-like 1, basal-like 2, mesenchymal, and luminal androgen receptor) [4, 5]. These studies have
revealed the complexity of breast tumors and generated many new hypotheses for potential
therapeutic targets for treatment of TNBC.
TNBC is one of the subtypes of breast cancer with an earlier onset, more aggressive
metastasis, and lacks the therapies available to ER+, PR+, and HER2+ breast cancers [3]. Fiveyear breast cancer survival is significantly reduced with diagnosis of TNBC [6], due largely to
relatively ineffective therapeutic options [7]. There is therefore a need to identify new, effective
targets for TNBC.
All cells maintain a polarized membrane potential (Em), more negative inside than outside
the cell membrane. Em is essential to the development of action potentials in excitable cells such
as neurons and cardiac myocytes. However, accumulating evidence has also demonstrated
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variability of Em in non-excitable epithelial cells and cancer cells as well [8]. Alterations in Em
(depolarization – i.e. Em becoming more positive, hyperpolarization – Em becoming more
negative) are now recognized to play a crucial role in controlling the cell cycles [9, 10].
Using a traditional microelectrode technique, Em was reported to be -13mV in breast
cancer biopsy specimens from nine women with infiltrating ductal carcinoma, independent of ER
or PR presence [11]. For comparison, normal human breast epithelial cell Em is near -60mV [11].
Thus, Em is depolarized in breast cancer compared to normal breast cells. Using whole-cell patch
clamp, we found more positive Em in TNBC MDA-MB-231 cells (-39.5mV) than in normal breast
cells (-66.9 mV) [12].
KCNMA1 gene encodes the pore-forming alpha subunit of a voltage- and calcium-gated
large-conductance potassium channel, called BK (also known as Slo1, Maxi-K, or KCa1.1)
channel [13, 14]. Previous studies have suggested a contradictory role of KCNMA1 in breast
cancer proliferation, invasion, and metastasis. Blockade of BK channels can slow proliferation and
invasion of breast cancer cells [15, 16]. In contrast, studies with anti-tumor compounds revealed
anti-tumor action as an important result with activation of BK channels in metastatic breast cancer
cells [17].
BK channels have to open (activate) to exert their function – hyperpolarizing Em by loss
of intracellular potassium ions. Therefore, high expression of KCNMA1 does not necessarily
guarantee high activity because closed channels do not have activity and cannot hyperpolarize the
cell. Similarly, low expression of KCNMA1 expression levels can have a significant impact if all
channels are open. Therefore, the strategy to inhibit or activate BK channels can only be decided
after we determine if the channels are open or closed at the Em of TNBC cells.
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In this work, we present evidence for overexpression of KCNMA1 in TNBC from a large
dataset. Second, we verify a significant increase in protein expression of BK channels in TNBC
cell lines and primary TNBC tissues. Third, we provide an answer to an intriguing question
regarding how breast cancer cells remain depolarized while overexpressing a hyperpolarizing ion
channel, which should make cell membrane potential more negative. Fourth, we demonstrated that
opening BK channels hyperpolarizes Em and induces apoptotic death of TNBC cells via apoptosis.
Fifth, we show that BK channel openers can slow tumor growth in an MDA-MB-231 xenograft
model in female NSG mice to validate the main in vitro finding. Finally, we show that this new
approach of using BK channel openers for selective induction of death in TNBC does not impact
healthy breast tissue and cardiac function.
Methods
KCNMA1 gene expression in The Cancer Genomic Atlas (TCGA) database
KCNMA1 gene expression patterns in primary breast cancer database were analyzed from The
Cancer Genome Atlas (TCGA) [18] via cBioPortal (http://cbioportal.org ) [19]. Gene expression
levels from RNA-sequencing data was illustrated in log2-fold of fragments per kilobase of
transcript per million (FPKM) [20].
Cell culture and plasmid transfection
Human breast adenocarcinoma cells (ER+ MCF7, triple-negative MDA-MB-231/Luc and
SUM159) were grown in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen), whereas
triple-negative HCC1143 cells were grown in RPMI (Invitrogen), supplemented with 10% fetal
bovine serum, 1X Pen/Strep (Gbico 15140). Normal human mammary epithelial cells (MCF10A)
were grown in mammary epithelial cell basal medium (MEC), supplemented with MEC growth
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kit (ATCC). Rat h9c2 cardiac myocytes were purchased from ATCC (CRL-1446), cultured in
DMEM.
Cells with 50-70% confluence in 6-well plates were used for transient plasmid (1-2g)
transfection using Lipofectamine3000 transfection reagent (Invitrogen). Human wild type (hSlo1
WT) and A313D mutant (hSlo1-A313D) channel cDNA in pcDNA3 mammalian expression vector
were co-transfected with GFP for verification of expression.
Patch clamp studies in MDA-MB-231
Details in whole-cell or perforated (or permeabilized) patch clamp studies in isolated cells
have been previously reported [21, 22]. Briefly, the cells grown on coverslips were placed in a
lucite bath with the temperature maintained at 35oC - 37oC. Em and voltage-gated potassium
currents were recorded using the whole cell patch clamp technique with an Axopatch-700B
amplifier. Em was measured with DMEM or Tyrode solution and pipette solution. DMEM
contained physiological ion concentration (in mM): 150Na+, 5K+, 2.0Ca2+ (pH = 7.4). Tyrode
solution contains (mM): NaCl 140, KCl 5.4, CaCl2 1.8, MgCl2 1, Glucose 5.5, Hepes 5, pH 7.4
adjusted by NaOH. The pipette solution contained (in mM): 85 KCl, 40 K-Aspartate, 0.1CaCl, 10
HEPES, pH was adjusted to 7.2 by KOH. The pipettes had a resistance of 2–5 M when filled
with pipette solution. For perforated patch, amphotericin - B was added to the pipette solution to
a final concentration of 240g/ml. The whole-cell/perforated patch clamp data were acquired by
CLAMPEX and analyzed by CLAMPFIT (pClamp 9, Axon/Molecular Device).
Live cell imaging
Live cell imaging experiments were performed using a Zeiss Axio Observer A1 inverted
microscope with fluorescence. Images were acquired and analyzed using AxioVision (version 4.6).
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We used ethidium homodimer-1 (EthD-1, Invitrogen, 0.2-0.5l of 2mM stock to 1ml culture of
cells in 6-well plates) to label dead cells. Cell count was performed using ImageJ (NIH).
Western blotting
Cells were harvested using Radioimmunoprecipitation Assay (RIPA) buffer with 1%
protease inhibitor cocktail (Sigma). We then sonicated lysates on ice and centrifuged at 12,000xg
for 10 minutes at 4oC. Tumor tissue was homogenized in RIPA buffer with 1% protease inhibitor
cocktail (Sigma), then centrifuged at 12,000xg for 10 minutes at 4oC. Supernatant was isolated
from debris pellet.
Protein concentration was measured using Bicinchoninic acid assay (BCA) (Thermo
Fisher). Once protein concentrations were normalized across samples, they were then heated for
12 minutes at 90oC. Samples were loaded into NuPage 4–12% bis-tris gels (Invitrogen) with
MOPS running buffer at 70 volts for 100 minutes, then transferred to 0.2 m pore PVDF
membrane (Thermo Scientific) at 30 volts for one hour in cold room. Next, blots were blocked in
Licor blocking buffer for one hour, and incubated for 12 hours at 4 degrees with primary antibody
for either anti-KCNMA1 for epitope 199-213 (Alomone cat# APC-151), anti-caspase-3 (Cell
Signaling Technology), or anti-Slo1 for c-terminus segment 9-10 (Millipore) at 1:500 dilution.
The membrane was then washed 3 times for 15 minutes with tris-buffered saline containing 0.1%
tween-20 (TBS-T). A secondary antibody, IR 800 CW from Licor (1:20,000 dilution) was
incubated with the membrane at room temperature for one hour. After three 10-minute washes
with TBS-T, blots were imaged using a Licor Odyssey CLx and image studio software. If residual
background signal was observed, additional washes of 5 to 10 minutes with TBS-T were
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completed and the membrane was re-imaged. Beta-actin primary antibody (Proteintech) and
IRDye 680RD secondary antibody (Licor) were used as a loading control.
Immunohistochemistry of patient breast samples
Experiments involving patient breast samples were approved by West Virginia University
Institutional Review Board. Formalin-fixed paraffin-embedded (FFPE) breast tumor tissue from
patients was processed according to vendor’s manual instruction (Biocare) and following a verified
protocol in the Pathology Laboratory of Translational Medicine at WVU. Briefly, 3m sections
were deparaffinized on slides, quenched with hydrogen peroxide, and incubated in BK channel
antibody (Sigma-Aldrich, HPA054648) Sigma at 4oC for 4 minutes. Horseradish peroxidasecontaining secondary antibody (UMap anti-RB, Roche, Diagnostic, Cupertino, CA) was then
added for 8 minutes and developed using Biocare DAB (brown color). Hematoxylin was used as
a counterstain (blue color).
Automated formalin-fixed, paraffin embedded immunohistochemical staining, to evaluate
tumor antigen expression profiles, is available via the Ventana DISCOVERY automated IHC
Platform. Breast tumor IHC slides stained with BK channel antibody were examined under an
Olympus VS-120 slide scanner with a 10X Plan S Apo/0.40 NA objective, equipped with a color
camera (Pike 505C VS50). The images were analyzed using OlyVIA (Olympus) and ImageJ
(NIH). Percentage of area staining was used to quantify the protein expression levels in IHC slides.
Breast tumor induction in NOD scid gamma (NSG) mice
Female NSG-immunodeficient mice of 4-6 weeks old were purchased from the Jackson
Laboratory. Experimental procedures and housing of the animals were approved by the
Institutional Animal Care and Use Committee. Animal were housed in a fully state-of-the-art
facility that includes large specific pathogen free rooms, husbandry conditions (breeding program,
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light/dark cycle, temperature control, quality water, clean cages access to food and water), and
welfare-related policies related to tumor studies (e.g., tumor burden policy).
Following power analysis, a total of 16 female mice was used, 8 for treatment, 8 for
controls. For mammary pad injections, pathogen-free luciferase-expressing human breast
adenocarcinoma cells (MDA-MB-231/Luc, 1-2x106 cells/animal) were injected into the fourth
inguinal mammary gland of 6- to 8-week-old mice. Primary tumors had formed typically two
weeks following cell injection. Tumor size was monitor by imaging twice a week. After
experiment, mice were euthanized by isoflurane overdose (5% to effect or an overdose 100mg/kg
of sodium pentobarbital), a procedure approved by our IACUC.
Ultrasound imaging of xenograft tumor in NSG mice
Details for ultrasound imaging of xenograft tumor in NSG mice have been previously
reported [21]. Briefly, animals were anesthetized by exposure to 1-3% isoflurane during imaging.
Imaging was performed weekly over the course of each experiment, typically for 4-6 weeks.
Tumor volume was imaged by ultrasound imaging (USI) with Vevo2100 Micro-Ultrasound
System. A 40 or 50 mHz transducer was used, depending on the tumor volume. A 3-dimensional
(3D) image was acquired with scanning distance of 0.071 mm between images. Vevo software
then integrated the images into a reconstructed 3D tumor from which the tumor volume was
obtained.
BK channel openers
BMS-191011 (Tocris) and NS11021 (Tocris) were prepared in 10mM DMSO stock. The
working concentrations of 10-50M contained 1-5l of DMSO in 1 mL DMEM medium, resulting
in 0.1-0.5% of DMSO, which did not affect TNBC cells (Figure S7). For testing in vivo effects of
MDA-MD-231, 3l of 10mM (equivalent to 186.82ng) stock was added to 1mL PBS, 50l was
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administrated directly into the xenograft grown in mouse via during day time in the animal imaging
facility. For testing adverse effects of the drug, tail-vein injection was used.
Scratch (or “wound healing”) assay
MDA-MB-231 cells were incubated in a 24-well plate. After reaching 70% confluence, the scratch
(or “wound”) was created using a sterile 200-l pipette tip, defined by the space within two red
lines (upper left), filled (or “healed”) by migration of cells (upper right). Curved red line indicates
the marker (shadowed area) used to identify the location of the scratch.
Caspase-3/7 Green Fluorescence Dye
CellEvent Caspase-3/7 Green Detection Reagent was obtained from Thermo Fisher (Cat#:
C10723). Working solution of 1M was used in cell culture. Fluorescence microscopy was used
to acquire images. Green fluorescence was detected only apoptotic cells.
Cell cycle analysis using flow cytometry
Cells were grown to 60-80% confluency in DMEM before drug treatment. Cells were either
treated with BMS-191011 in DMSO, DMSO alone, or no treatment. After 24-48 hours, cells were
washed with PBS and incubated with 0.25% trypsin with EDTA (Invitrogen) for 5 minutes at 37oC.
After combining the resultant solution with 10mL PBS in 15mL tubes, cells were pelleted at
1000rpm for 6 minutes at 4oC. Cell pellets were resuspended in 200L PBS then added with
swirling to 2mL ice cold 70% ethanol. These single-cell suspensions were kept at 4oC until further
processing.
For flow cytometry, cells were re-pelleted at 1000rpm for 6 minutes before decanting
ethanol. After resuspension in 2mL PBS and incubation for 1 minute at room temperature, cells
were pelleted and resuspended in 100L of 0.2% Tween-20 in PBS at room temperature then
incubated at 37oC for 15 minutes. Next, 100L of PBS containing 2% fetal bovine serum and 0.1%
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sodium azide was added and cells were pelleted. The solution was then decanted, 10L of RNase
A (DNase- and protease-free; Thermo Scientific EN0531) in PBS (180g/mL) was added and
allowed to sit for 15 minutes at room temperature, and 20L of propidium iodide (PI) in PBS
(50g/mL) was added for 15 minutes. The resultant solution was brought to a volume of 300500L using PBS before data collection.
Samples were analyzed on BD LSRFortessa using BD FACS Diva version 8.0 software. A
minimum of 20,000 cells were collected for each sample. Data analysis was done using FCS
Express 6.0 flow cytometry software (De Novo Software, Los Angeles CA). Cell cycle fit
algorithm was selected using the lowest relative chi square value and BAD value < 20%.
Statistical analysis
Data were shown as mean  standard deviation (SD) in the text. Bar figures were presented
as mean  SD using GraphPad (Prism). Student’s t-test and two-way ANOVA (for more than two
groups) were used for statistical analysis. P<0.05 was considered as statistically significant. Details
in statistical analysis, such as F values and degree of freedom (DF) when using ANOVA and t
values when using t-test, are included in the figure legends.
Results
1) KCNMA1 gene and protein expression in breast cancer patients
We used gene expression data (RNA-seq) from 981 breast cancer samples (TCGA Cell
2015 [23] and TCGA Provisional). In all five subtypes BK channel KCNMA1 gene expression
levels are dramatically upregulated, comparison to normal breast cells (FPKM ~ 0.7) (Figure 1).
TNBC patients are represented by red dots.
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Using transcriptomics and a targeted proteomics approach, the gene-specific correlation of
mRNA levels and protein copy number has been well established in human cells and tissues [24].
Previous studies have demonstrated that BK channel alpha subunit protein (main subunit forming
the pore of the channel) is abundantly expressed in MDA-MB-231 cells, weakly expressed in
MCF7, and nearly undetectable in normal breast epithelial cells MCF10A [15]. Therefore, we set
out to investigate the protein expression of BK channels in TNBC patients’ tissues.
Figure 2 shows a representative figure for protein expression of BK channel alpha subunit
in primary TNBC tissue using an antibody that targets an epitope in the 1st extracellular loop of
transmembrane domains 1 and 2 (corresponding to amino acid residues 199-213 of rat KCNMA1
(Alomone Labs). MDA-MB-231 (MDA231 in the figure) was used as a positive control. Mouse
brain (MB) known to express BK channels [25, 26] was used as an additional positive control
(stronger signals in a more sensitive fluorescence image of Western blot). In addition to the
glycosylated channel protein (around 200kD), there exist smaller fragments recognized by the
antibody that are likely the proteolyzed C-terminals of the channel protein reported in previous
studies [27]. The interpretation of the results was confirmed by incubation of the antigen (2B) that
showed disappearance of the signals in 2A. After total expression signals being normalized to actin, BK channel protein expression levels are nearly 14-fold higher in primary TNBC than in
normal human breast tissue (Normal: 0.345±0.177; TNBC: 4.793±1.074, n=4-6, p<0.001) (2C).
Figure 2D shows that BK channel proteins are also abundantly expressed in different types of
TNBC cells (SUM159, HCC1143), but barely detectable in MCF10A normal breast cells.
To confirm the increased protein expression levels of BK channels in TNBC patients, we
performed IHC experiments in seven TNBC tissue and three normal breast tissue samples. We
used a BK channel antibody that had been successfully applied in identifying KCNMA1 channel
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protein expression in the Human Protein Atlas (Sigma-Aldrich, HPA054648). Supplemental
Figure 1 shows a normal breast tissue (A) and a TNBC tissue (B). The averaged percentage of
protein expression area is shown in (C). BK channel protein levels were increased by ~ 9-fold in
TNBC than in normal breast tissue (TNBC = 3.56±1.33, n=7; Normal = 0.41±0.10, n=3; p<0.01).
Figure 1 raised several questions: 1) Why are depolarized TNBC cells overexpressing a
hyperpolarizing BK channel? 2) Are these overexpressed BK channels activated (open)? These
questions led us to the hypothesis that these overexpressed BK channels are not activated. If this
hypothesis is correct, then opening these channels can be exploited as a novel strategy for targeted
therapy in treatment of TNBC.
For ion channels whose activity is dependent on Em, gene/protein expression levels are not
intrinsically correlated with channel activity. At the resting Em of the cell, ion channels are active
when they are open, inactive when they are closed. We therefore set up to investigate biophysical
properties of BK channels in TNBC cells.
2) Voltage-dependent activation of BK channels in TNBC cells
Previously, we showed that the resting Em, which is within the physiological voltage range,
in MDA-MB-231 cells is depolarized compared to normal mammary epithelial cells (HMEC)
(Em_MDA-MB-231: about -40mV, Em_HMEC: about-67mV) [12]. To investigate whether BK
channels in MDA-MB-231 are open at -40mV, we studied biophysical properties of BK channels
in MDA-MB-231 cells using whole-cell and perforated patch clamp techniques.
Figure 3A shows the typical BK channel currents activated by the depolarizing pulse
protocol (below 3A). The currents were confirmed to be generated from BK channels by
iberiotoxin (IbTX, 100nM) (known as a potent specific blocker of BK channel (with IC50 of
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250pM) since it does not affect other ion channels [28]). Figure 3B shows the average voltagedependent activation curve of BK channel in eight (8) MDA-MB-231 cells. At -40mV (resting Em
in MDA-MB-231), only 1% of BK channels are open.
3) BK channel opener hyperpolarizes Em in MDA-MB-231 cells
Opening large conductance (>200pS) [29] BK channels causes loss of intracellular K+ ions
to the outside of the cell, leading to membrane hyperpolarization. In MDA-MB-231 cells, we used
a potent selective BK channel opener, BMS-191011 (1M) [30] to study how opening BK
channels may affect cell Em. We found that BMS-191011 (1M) hyperpolarized Em by 15mV
(Em_con = -30.71±8.20mV, Em_BMS = -45.86±8.95mV, n=8; p<0.01) within 15min of
application (Figure 3C). IbTX (100nM) did not induce significant change in Em (Em_con = 30.71±8.20mV, Em_IbTX = -30.86±6.64mV, n=8; p>0.05), but completely reversed
hyperpolarization induced by BMS-191011 (Em_con = -30.71±8.20mV, Em_BMS+IbTX = 28.43±7.30mV, n=8; p>0.05) (Figure 3C). The results provided additional evidence that the
majority of BK channels are closed at Em in MDA-MB-231 cells.
4) BK channel opener induced death of human TNBC cells
To test whether hyperpolarization by opening BK channels can induce death of TNBC
cells, we studied effects of BK channel opener in TNBC cell lines. Treatment of BMS - 191011 at
20M for two days did not affect normal breast MCF10A cells (Supplemental Fig.2, left panels),
but dramatically induced cell death of MDA-MB-231 cells (Supplemental Fig.2, middle panels).
BMS-191011 halted growth of MCF-7 cells but induced death of much fewer cells compared to
MDA-MB-231 (Supplemental Fig.2, right panels). Figure 4A shows the percentages of
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dead/dying cells are 0.92 ± 0.29% (n=5) for MCF10A, 14.76±1.94% (n=5) for MCF-7, and
63.82±6.21% (n=5) for MDA-MB-231, p<0.0001 (One-way ANOVA).
To ensure that BMS-191011 induced cell death is via opening BK channels, we used
another specific BK channel opener, NS11021, which has a different chemical structure [31].
Figure 4B shows time - and concentration – dependent effects of NS11021 on the growth of MDAMB-231. At day 5, most cells treated with 20M NS11021 were dead (Supplemental Fig.3). For
the same day, NS11021 induced cell death at different concentration is statistically significant
compared to untreated group (p<0.0001, n=6).
To test whether BK channel opener mediated hyperpolarization-induced cell death is
independent of TNBC subtypes, we studied effects of BMS-191011 on additional TNBC cell lines,
SUM159 (Basal A, like MDA-MB-231) and HCC1143 (Basal B) [32]. BMS-191011 inhibited cell
growth of SUM159 (4C) (and Supplemental Fig.4) and HCC1143 (4D) (and Supplemental
Fig.5) cells in a similar way compared to that in MDA-MB-231. Additional controls were
performed to rule out the potential side effects of DMSO on the cell growth of TNBC.
Supplemental Figure 6 shows an example for 0.5% DMSO (maximal volume used in drug
treatment) that has no effect in cell death of HCC1143. We also tested that DMSO had no effects
in cell growth of MDA-MB-231 and SUM159 cell lines.
Additionally, we tested whether a mutated BK channel that is permanently open (A313D),
leading to hyperpolarization [33] may induce MDA-MB-231 cell death. Supplemental Figure 7
shows that after 2 days of transfection, 59.4±13.7% (n=5) of MDA-MB-231 cells expressing
A313D died, in comparison to 17.2±5.3% (n=5) of death in cells expressing wild-type (WT)
channels or 18.8±7.4% of death in cells expressing on GFP plasmid (n=5, p<0.003). After 4 days
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of transfection, all MDA-MB-231 cells expressing A313D were dead, whereas most cells
expressing WT channels or GFP alone were alive.
5) BK channel opener induced apoptosis and caspase-3 activation in TNBC
To understand the mechanism that mediates hyperpolarization - induced death in TNBC
cells, we studied apoptosis, a well-studied programmed cell death mechanism. We performed timelapse imaging experiment demonstrating that low concentration (1M) of BMS-191011 induced
rapid cell shrinkage, a distinguished event unique to apoptosis [34], within 20-60min
(Supplemental Fig.8).
We also studied effect of BK channel opener in caspase activation, an established
mechanism and a strong indicator of apoptosis [35]. We first used a fluorescent caspase 3/7 green
dye to test whether BK channel opener may induce caspase activation in MDA-MB-231. Figure
5 shows that after 3 days of 10M BMS-191011 treatment (5A), strong fluorescent signals (5B)
were detected in MDA-MB-231. Furthermore, Figure 5C shows the presence of pro-caspase-3
protein expression in three TNBC cell lines, MDA-MB-231, HCC1143, and SUM159. BMS191011 (20M) treatment for two days induced cleaved caspase-3 expression in MDA-MB-231
(5D). These results suggested that BK channel opener can induce caspase-3 activation in MDAMB-231 cells. Thus, hyperpolarization can induce activation of caspase-3 and apoptosis in TNBC
cells.
6) BK channel opener prevented migration of MDA-MB-231
Majority of breast cancer patients die due to tumor metastasis and one critical step of
metastasis is migration [36]. If BMS-191011 effectively induced cell death, it may prevent
migration of MDA-MB-231 cells. Supplemental Figure 9 shows a typical scratch assay (or
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“wound heal”) imaging experiment [37]. While control (untreated) MDA-MB-231 cells can
recover from the scratch within 4 hours (upper), 100nM BMS-191011 prevented migration of
MDA-MB-231 cells within 4 hours (lower). Similar results were obtained in an additional four
experiments.
7) BK channel opener induced arrest in cell cycle G2 phase in MDA-MB-231
Figure 6 shows the effect of opening BK channels in MDA-MB-231 cell cycle using flow
cytometry. In the absence of BMS-191011 treatment, cell distribution in G1/S/G2 phases are
approximately equal (A), BMS-191011 treatment after 24h resulted in arrest in S/G2 phases
associated with a decrease distribution in G1 phase (B). After 48h, cells are all arrested in G2 phase
(C). As a control, we showed that DMSO (1%) had no effects on cell cycle in MDA-MB-231 cells
after 24h treatment (Supplemental Fig.10). Similar results were repeated in an additional three
experiments.
8) BK channel opener induced slower growth of MDA-MB-231 xenograft in NSG mice
To test the inhibitory effects of BK channel opener on TNBC tumor in vivo, we generated
MDA-MB-231 xenograft in female NSG mice at 4-week old age [21]. After a sizable tumor was
formed (typically after 1-2 weeks of cell injection), BMS-191011 at 100g/kg (or 1-2g/mouse)
was directly injected into the tumor for better control of the dose and the potential loss of the drug
due to rapid metabolism in mice. The drug was given twice a week in the treat group. For control
group, saline was given twice a week. To avoid large variation in tumor sizes due to heterogeneity
of breast cancer, we selected pairs of tumors (one as a control – injected PBS only, the other treated
– injected drug in PBS) that had similar tumor sizes, and performed ultrasound imaging for four
weeks to monitor effect of BK channel opener during the growth of tumors.
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Figure 7 shows a representative example for three pairs of control and treated tumors. The
injection of the drug began at week5 when three pairs (C1/T1, C2/T2, and C3/T3) had similar
tumor sizes, the treated tumor (T) grew significantly slower than the control tumor (C) each week
(7A). In week 8, averaging data showed a 33% reduction of tumor volume in drug-treated group
(T= 710±105, n=8) compared to the control group (C=1056±106, n=8) (p<0.05) (7B).
9) BK channel opener and cardiotoxicity
Cardiac toxicity is a major concern in anti-cancer drugs [38]. Supplemental Figure 11
shows the echocardiograph results for MDA-MB-231 xenograft mice treated with a high dose
(0.1mg/kg) of BMS-191011 compared to control (PBS treated) mice (n=3). There are no
significant differences (p>0.05) between the two groups in cardiac function including heart rate,
ejection fraction, left ventricular mass, and cardiac output.
Additionally, we co-cultured MDA-MB-231 with the cardiac myocytes to test the
hypothesis that BK channel opener can only induce cell death in MDA-MB-231 but not in cardiac
myocytes due to extremely low expression levels of KCNMA1 gene in the heart. Supplemental
Figure 12 shows that BMS-191011 at 20M indeed induced cell death only in MDA-MB-231
with little effects in cardiac myocytes after six-day incubation.
Discussion
In the present work, we showed evidence to support a hypothesis that targeted treatment
by activation of BK channels - thereby hyperpolarizing the Em - can induce cell death in TNBC
while sparing healthy breast cells without cardiac toxicity. We selected a BK channel opener due
to overexpression of the channels in breast cancer and large conductance of the channel. Opening
large conductance potassium channels can effectively induce membrane hyperpolarization due to
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rapid efflux of K+ ions. Extremely low expression of BK channel gene expression in normal breast
cells and cardiomyocytes ensures selective apoptosis in TNBC and absence of cardiac toxicity by
BK channel opener.
Using microarrays, KCNMA1 gene expression was found to increase in several cancers
including breast cancer [16]. Using RNA-seq data in a large breast cancer dataset in TCGA, we
found overexpression of KCNMA1 in all subtypes of breast cancer. In principle, our approach of
using BK opener for selective induction of cell death works for all subtypes of breast cancer. We
focus on TNBC due to lack of targeted therapy in TNBC. It needs to be emphasized that mutations
in KCNMA1 gene are rare – only 15 (7 in luminal A, 5 in luminal B, 2 in HER2, 1 in basal subtype)
in breast cancer, although the gene is overexpressed and the cause of overexpression is unknown.
We verified that the BK channel alpha-subunit protein levels are significantly increased in
MDA-MB-231 and in TNBC patient tissues compared to normal primary breast tissues. The
overexpression of BK channels in breast cancer would intuitively lead to interest in inhibition.
However, inhibition mandates that channels be active. This creates an apparent contradiction with
the overexpression of an ion channel that if it were active should make the Em more negative, yet
our research demonstrates a cell with a more positive (depolarized) resting Em. This contradiction
can be resolved if the BK channels are not open at resting Em in TNBC. The lack of statistically
significant correlation of relapse free survival rate with expression confirms the need to look
beyond channel expression to channel function to answer this question of inhibition or activation.
We performed patch clamp studies and found that indeed <1% of BK channels are open at
-40mV, which is near the Em in MDA-MB-231 cells [12]. This result addressed the problem of a
depolarized breast cancer cell overexpressing hyperpolarizing BK channels. This result also
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opened a new idea that opening BK channels in breast cancer cells should hyperpolarize Em, which
may halt cell growth.
We tested this concept in three TNBC cell lines, MDA-MB-231, SUM159, and HCC1143,
representing different subtypes of TNBC. We used two structurally different openers (BMS191011 and NS11021) to ensure that any effects seen in cell growth are mediated by BK channel
opening. Notably, BK channel openers induced more cell death in MDA-MB-231 than in MCF-7
(a non-metastatic breast cancer cell line). One possible explanation is that BK channel protein
levels

are

significantly

higher

in

MDA-MB-231

than

in

MCF-7.

Indeed,

using

immunofluorescence staining BK channels have been previously reported to be abundantly
expressed in MDA-MB-231, very weak in MCF-7, and undetectable in MCF10A [15].
Additionally, we employed a constitutively opened mutant BK channel to demonstrate that
hyperpolarization is the primary driving force to induce cell death in TNBC cells.
To explore cellular mechanisms that mediate the hyperpolarization-induced death in TNBC
cells, we showed in MDA-MB-231 cells early morphology changes (shrinkage) and late activation
of caspase-3 in MDA-MB-231 cells. Normotonic shrinkage of cells is a hallmark of apoptosis [34].
Caspase activation is a well-established pathway in apoptosis [39]. In addition, we showed that at
low concentration (100nM), BK channel opener was able to prevent cell migration.
During cell cycle, membrane depolarization is essential for transition of G2-phase to
mitosis [9, 10]. Induced hyperpolarization during this transition can arrest cell growth by blocking
DNA synthesis [9, 10]. Indeed, our results demonstrated that hyperpolarization induced by BK
channel opener caused cell cycle arrest in G2 phase in MDA-MB-231.
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In three size-matched tumor pairs, BMS-191011 slowed down the growth of xenograft
tumors every week, indicating that opening BK channels in tumor can inhibit cell growth of TNBC
cells in vivo. After four-week treatment, there was a statistical difference between the two groups,
even using a small number of mice (8 per group) and twice a week drug treatment. Increasing
number of mice and frequency of drug treatment may likely demonstrate a stronger statistical
significance with a larger inhibitory effect in xenograft tumor growth.
A major concern in anti-cancer drugs is cardiotoxicity [38]. The KCNMA1 gene expression
levels are very low in the heart (FPKM  0.2 to 0.3) [40]. We performed echocardiogram on the
mice to assess potential cardiac side effects of BK channel opener in cardiac functions. We found
no significant changes in cardiac functions in treated mice compared to untreated mice.
Furthermore, in the co-culture of TNBC cells with cardiac myocytes, we showed that BK channel
opener did not induce significant toxicity in cardiac myocytes, while killing TNBC cells.
Targeted therapy has significantly increased the survival rate of breast cancer patients,
while cardiotoxicity remains an increased risk of cardiovascular disease (such as left ventricular
dysfunction and heart failure) in breast cancer treatment [41]. For older women (>65 years)
surviving breast cancer, the leading mortality is cardiovascular disease, not breast cancer itself
[41].
Ion channels play a critical role in the hallmarks of cancer [42]. Gating of voltagedependent ion channels are controlled by cell membrane potential (Vm). Opening and closing of
these channels also change Vm. For example, opening of K+ channels causes membrane
hyperpolarization (Vm becomes more negative) due to K+ ions flowing out of the cell [43, 44]. On
the other hand, opening of Ca2+ channels increases calcium influx ([Ca2+]o ~ 1-2mM, [Ca2+]i ~
100-200nM), which contributes to membrane depolarization (Vm becomes more positive) .
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Calcium homeostasis is an extremely delicate process, disruption of calcium homeostasis triggers
many pathological events including apoptosis [46, 47]. Many ion channels are overexpressed in
cancer cells, but nearly undetectable in normal epithelial cells. For example, voltage-dependent
calcium channels (VGCC) are readily detectable in breast cancer cells [48, 49], but not in human
healthy mammary epithelial cells . Therefore, we demonstrated that blocking VGCC can
effectively inhibit growth of breast cancer cells without affecting normal breast cells .
Recently, voltage-gated potassium channels have attracted cancer investigator for being
potential targets in cancer therapy [51, 52]. Kv1.3 has gained particular attention due to its low
expression in the heart, while overexpressed in cancer [53, 54]. We are targeting BK channel since
it has the largest conductance in the potassium channel family. Opening BK channels therefore
can induce the largest membrane hyperpolarization, a central strategy to breast cancer cells in
which membrane potential is depolarized. BK channel expression levels in heart (RPKM ~0.2)
is even lower than in normal breast cells (RPKM ~0.7), targeting BK channel activation is
anticipated to have significantly less effects in cardiac functions.
Conclusions
While KCNMA1 genes are overexpressed in all types of breast cancer, targeting it is
particularly useful for TNBC due to lack of effective pharmacological therapy in TNBC patients.
We propose a novel approach to inhibit TNBC growth based on depolarized Em and significantly
increased BK channel gene expression in TNBC. This new strategy is independent of TNBC
subtypes and yields tumor-specific destruction of TNBC without cardiac toxicity.
Summary
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The evidence in this research for targeted treatment of TNBC with this BK ion channel
demonstrated, not only the novel discovery for treatment possibilities in TNBC, but also the
significant role electrophysiology can play in granting functional insight to genetic data which
translates to clinical understanding of disease and future opportunity for application. This next
section reveals the circle of clinical translation when an epidemiology study shows a multi-gene
signature test which could identify electrophysiology ion channel targets is not only underutilized
but may contribute to why there is exponentially increased tumor growth in TNBC patients with
age at diagnosis.
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CHAPTER FOUR
Triple Negative Breast Cancer: Exponential Tumor Grade Increase with Age of Diagnosis
Abstract
Triple negative breast cancer is an aggressive breast cancer with decreased five-year survival,
increased risk for recurrence, and higher risk for metastases. Unlike other breast cancers, it has
no targeted treatment and has heterogenous genetics which make classification and treatment
difficult. The purpose of our research was to compare triple negative breast cancer to non-triple
negative breast cancer to identify key epidemiologic factors that might lead to improved basic
science directives for biomarkers, treatments, and classification. Our research uses the state
cancer registry to provide the first West Virginia state-wide population evaluation of triple
negative breast cancer. The research reveals novel results that tumor grade increases
exponentially with the age at diagnosis. This creates an epidemiological foundation for future
research to define whether the disease, access to care, biology of aging, or some other factor
cause this significant finding. In addition, results reveal decreased use of testing that could be
increased to improve biomarker identification, targeted treatments, and classification of triple
negative breast cancer.
Introduction
World-wide, breast cancer is a leading cause of cancer mortality in women1 and in the United
States, invasive breast cancer impacts 12.4% of the population of women.2 Breast cancer is a
diverse disease with five molecular subtypes. One type is triple negative breast cancer (TNBC),
a breast cancer where tumors are negative for estrogen receptor, progesterone receptor, and
Human Epidermal Growth Factor Receptor 2 overexpression.3,4 Because of its heterogeneity,
TNBC is further divided into sub-types whose classification is still controversial with the most
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recent being the genetic profile classification.5 TNBC is an aggressive disease and is associated
with a poorer prognosis and 5-year survival rate as there is a higher risk for recurrence and
metastasis among affected patients.6,7,8 Previous studies have shown that the prevalence of
TNBC is higher in some demographic groups such as women under 40 years of age and among
women of black race or Hispanic ethnicity.9,10,11,6,12,7,13,14 The reasons as to why certain
demographic groups are more affected than others are unknown. Previous studies have proposed
that obesity, diet, genetics, socioeconomic, and biological factors may explain differences seen
among demographic groups in terms of TNBC.11,6,7,15,3,16,8
Because of the severity of TNBC, there has been an increased interest in investigating
demographic, diagnostic, and prognostic factors associated with the disease not only nationwide,
but also in West Virginia.9,8,17 The age-adjusted breast cancer mortality rate among women in
West Virginia is the 8th highest among states.18 In addition to the high mortality rate, West
Virginia’s population is somewhat homogenous compared to other states as over 94% of the
population is White Non-Hispanic;19 thus, racial differences may be observed to a lesser extent.
However, the population is of lower socioeconomic status and has greater levels of obesity
compared to most other states.20,21 The state also has a low net migration of residents which
could indicate that hereditary factors associated with TNBC, such as BRCA mutations, may
remain present in the population and influence the disease’s prevalence.3,22
To date, two studies have investigated TNBC in West Virginia.8,17 One study found that West
Virginia patients had increased representation of advanced tumors at time of diagnosis.17 The
other study determined that a greater proportion of women with TNBC were under the age of 50
and that their tumors were larger than non-TNBC patients; TNBC patients also were slightly
more obese than non-TNBC patients.8 However, both studies utilized unique patient populations
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from a university hospital and/or a regional medical center over 15 years ago. Thus, the purpose
of this study was to investigate the demographic and diagnostic differences between those
diagnosed with TNBC compared to non-TNBC utilizing more recent data from the state’s cancer
registry, which includes all patients diagnosed with breast cancer in the state. The findings of
this study could help inform future research in a state where cancer risk and mortality are high.
METHODS
Data source
The primary data source for this analysis was the West Virginia Cancer Registry, which is
maintained by the West Virginia Department of Health and Human Resources in Charleston,
WV. Since 1993, the registry maintains demographic and clinical data on individuals whom are
diagnosed and treated for cancer within the state. The registry also includes West Virginia
residents who were treated outside the state boundary, but retain a West Virginia address.23 The
registry collects, codes, and maintains these data in accordance to the National Cancer Institute’s
Surveillance, Epidemiology and End Results Program (SEER).24 The data are de-identified for
patient confidentiality purposes.
Study population
The study population included all West Virginia women who were diagnosed with breast cancer
(e.g. International Classification of Diseases for Oncology, Third Edition, codes C500-C509)
from January 1, 2010 thru December 31, 2016. The data years 2010-2016 were selected because
there were data quality concerns prior to 2010 and 2016 was the most recent data year available.
Human subject’s protections
This study was approved by West Virginia University’s Institutional Review Board (protocol
#1908679407).
Variables
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The primary dependent variable was whether an individual was diagnosed with TNBC (e.g.
dichotomous). TNBC was defined in accordance to SEER as a breast cancer that is negative for
estrogen receptors, progesterone receptors, and Human Epidermal Growth Factor Receptor 2
overexpression.24 Various independent variables were utilized for this analysis which included:
patient’s age at diagnosis, race, year of diagnosis, stage of cancer at diagnosis, whether their
cancer metastasized (binary), whether the patient’s ipsilateral axillary lymph nodes were
implicated (binary), whether the cancer was entirely insitu (binary), tumor grade, whether a
multigene test was performed on the patient (binary), and whether the patient was diagnosed
with Paget’s disease of the breast (binary). The categorization of these variables is shown in
Table 1. Race was dichotomized into white or other due the demographics of the state (e.g. it is
primarily White non-Hispanic).19 For tumor grade, some patients were given a BloomRichardson score. Those with scores 3-5 were considered low grade. Those with scores 6-7 or
8-9 were categorized as moderate and high grade, respectively.
Analyses
Because the objective of this study was to compare the characteristics of women in West
Virginia who were diagnosed with TNBC to other types of breast cancers, several analyses were
conducted. The demographic and diagnostic characteristics between those diagnosed with and
without TNBC were compared via frequencies and percentages. In order to determine which
variables were associated with TNBC in patients, both binary and multivariable logistic
regression analyses were conducted; these types of models were chosen because the outcome
was dichotomous.25 Unadjusted (i.e. binary) models were ran between each independent variable
and the outcome. All multivariable models were adjusted for age group, race, and year of
diagnosis. (However, it should be noted that the multivariable model for age group was only
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adjusted for year and race and the multivariable model for race was only adjusted for year and
age group). These models were adjusted for these variables because there are known differences
with TNBC diagnoses among different age groups and races in other clinical populations.9 Year
was also adjusted for because of the increasing awareness of TNBC in the literature overtime
which could potentially influence diagnoses.26 A third set of multivariable models were ran to
investigate potential effect measure modification. These models contained the same variables in
the first multivariable model but also included two interaction terms; there was one interaction
term between the independent variable of interest and age group and another interaction term
between the independent variable of interest and race.27 All data management and statistical
analyses were conducted in SAS/STAT software version 9.4 (Cary, NC) with two sided
significance level α=0.05.
RESULTS
Nearly 13% of the women diagnosed with breast cancer in West Virginia had TNBC (Table 1).
While nearly 60% of all breast cancer patients were over 60 years of age, a slightly larger
proportion of women ≤40 years of age were diagnosed with TNBC (7%) compared to those with
non-TNBC (4%). In regard to race, there was an increased percentage of non-whites (6%)
diagnosed with TNBC compared to the non-TNBC group (3%). The stage of cancer at diagnosis
confirmed a more aggressive cancer in TNBC with (4.2%) involving direct and lymph nodes
compared to non-TNBC (2.7%) and a distant cancer in TNBC (8.1%) compared to distant cancer
in non-TNBC (5.7%) at time of diagnosis. Metastasis was higher in TNBC (6.9%) compared to
non-TNBC (5.4%). Tumor grade differed in TNBC patients with 73.1% in high grade compared
to only 22.6% high grade in non-TNBC. While only 26% of patients with breast cancer received
a multigene test, only 6% of TNBC patients received it compared to 29% of non-TNBC patients.
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Table 2 shows the association between TNBC and demographic and diagnostic criteria. After
adjusting for race and year, the odds of TNBC diagnoses in women ≤40 was 2.2 times greater
than the odds of TNBC in women ≥71 years of age. The odds of a TNBC diagnosis in nonwhites was 71% higher than the odds of TNBC in whites after adjusting for age and year.
Additionally, it appeared that TNBC was associated with higher tumor grades. The odds of
TNBC was 16 times greater in high tumor grades than the odds of TNBC in women with low
tumor grades at time of diagnosis after adjusting for age, race, and year. Yet, the odds of a TNBC
diagnoses was 86% lower among those receiving a multigene test compared to the odds of a
TNBC diagnoses among those not receiving a multigene test.
Age was an effect modifier of the relationship between TNBC diagnoses and tumor grade (Table
3). After adjusting for both year and race, the odds of TNBC dramatically increased with more
severe tumor grades over the age groups. A female under the age of 40 diagnosed with TNBC
had 5 times greater odds of having a high tumor grade compared to the odds of a woman in the
same age group diagnosed with TNBC having a low- grade tumor. However, the odds of TNBC
for a female ≥71 years of age to be high grade stage was nearly 22 times greater than the odds of
a TNBC diagnoses for a female in the same age group having a low-grade tumor.
Age was also an effect modifier of the relationship between TNBC diagnosis and multigene test
conductance (Table 4). It appears that the conductance of the multigene test decreases with age.
While there were no differences in women ≤40, after adjusting for year and race, the odds of
TNBC diagnoses among 41-50 year-olds is 75% lower if multigene test is conducted compared
to the odds of a TNBC diagnoses among women of the same age who do not receive the
multigene signature test. However, the odds of TNBC diagnoses among ≥ 71year-olds is 88%
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lower if multigene test is conducted compared to the odds of a TNBC diagnoses among women
of the same age who do not receive the multigene signature test.
DISCUSSION
Several important findings were discovered as a result of this analysis. First, trends in TNBC
diagnoses typically seen in other studies were also seen in West Virginia. Secondly, TNBC
diagnosis and tumor grade varied by age, which is a novel finding. Thirdly, while multigene
testing was infrequently performed among all breast cancer patients, there was an inverse
relationship between age and multigene conductance among TNBC patients specifically. These
are important findings especially when considering the previous literature indicating delayed
diagnoses of breast cancer among West Virginia patients.17 This generates an imperative to
improve early diagnosis, treatment planning, and cancer typing.
In relation to the current literature, the findings were consistent with those of previous
nationwide studies. The prevalence of TNBC in West Virginia was 13%, which is similar to the
nationwide prevalence of 13%.9. Similarly, a there was a larger portion of patients under 40 years
old within the TNBC population when compared to the non-TNBC population. Also consistent
with the literature was the increased percentage of non-whites in the TNBC population despite a
94% white non-Hispanic population prevalence in West Virginia19,9, and confirmation of
TNBC’s aggressive form and increased risk for metastasis. However, the majority of TNBC
patients were older adults and there was a significant increased risk for high grade tumor in older
patients at time of diagnoses with TNBC.
The novel finding concerning TNBC diagnosis and tumor grade variation by age provides
opportunity for future research. The numbers are significant and may be due to biological
reasons such as decreased physiologic response with aging, access to care, a feature of the TNBC
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disease, or some other factor. The finding warrants additional investigation, perhaps using
national data.
We also found that multigene testing was not performed frequently, especially in TNBC patients,
and the test's frequency decreased with patient age. The cost, difficulty of coverage for testing,
and limitations of many tests in healthcare make this result unsurprising. However, the
increasing benefit of genetic and epigenetic research as well as improvements to the multigene
test itself may indicate opportunity for change. The data of this project indicates there may be
opportunity for improved patient outcomes with future research to identify barriers to its clinical
use.
New multigene signature testing provides American Joint Committee on Cancer (AJCC) staging
and molecular subtyping, both valuable tools for improving our ability to classify cancer types
and generate research data for identifying targeted treatment. Research by Lehman et al
discovered from retrospective pretreatment biopsies that prediction regarding neoadjuvant
response to therapy was not only possible but indicated the probability that there were both
chemotherapeutic sensitive and chemotherapeutic insensitive subtypes in TNBC.28 In addition,
research from multiple sources of basic science have linked cancer from the breast with the
upregulation of a gene, protein, or general pathway.29 For example, in 2009, there was
documentation of upregulation of hexokinase 2 in breast cancer brain metastasis linked with poor
prognosis.30 Thus, there is indication that multigene testing could assist evaluation of tumor to
aid typing and prognosis for future breast cancer patients. Multigene signature testing alone is
not the complete answer to identify targeted treatment, stratify risks, and improve outcomes of
clinical applications. However, improved use of this tool in conjunction with other clinical tools
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and parameters may improve patient stratification for treatment and lead to data for identifying
targeted treatments.
Conclusions
Our research is broad in its evaluation by use of the entire West Virginia breast cancer registry
data for our research. It is unique in its analysis to identify present evidence of TNBC disease in
West Virginia and its discussion of testing practice to raise pertinent questions. It is translational
in its combination of basic science and clinical application perspective.
TNBC in West Virginia is similar to the nation in its demographic evidence and its aggressive
nature. Our new finding of TNBC diagnosis and tumor grade variation by age urges future
research. While the discussion of Multigene signature testing reflects opportunity to evaluate
policy and practice for its use. Increased efforts are being made to extend multigene testing to
whole genome evaluation of tumors to bolster the information we glean from tumors.31
Therefore, increased use of the multigene signature tool may improve our ability to develop
biomarkers for early identification of disease, targeted treatment, and response to therapy.
Evaluation regarding our finding of exponential increase of high-grade tumor findings with
increased age at diagnosis and evaluation of constraints impacting the use of the multigene
signature test could be beneficial epidemiologic ventures for future research. Our research
supports the need for increased focus on tumor evaluation and early diagnosis to improve
outcomes for patients.
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CHAPTER FIVE
Discussion and Translational Significance
The focused interweaving of this collected work thus far allows for unique understanding of the
tool of electrophysiology, its significant role in generating functional data to establish a novel
target for disease treatment in TNBC, and its translational potential to extend the circle of clinical
translational science with epidemiologic evidence that clinical testing, if properly appraised and
policy supported, can continue the cycle and turn breast cancer pathology into biomarkers, and ion
channels into targets.
This relationship between the electrophysiologic impact of specific ion channels in resting
membrane potential of the cell lines of triple negative breast cancer and the in vivo impact of
treatment targeting those ion channels demonstrates the opportunity of electrophysiology to create
a translational platform from basic science to clinical medicine. Clinical translational science
proposes a gambit to provide research that is both basic science and clinical application in its
promise.
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CHAPTER SIX
Methods
The specifics of solutions, measurements, equipment, and technique are listed in detail within the
individual manuscript projects for reproducibility. This section proposes to present a broader
understanding of the methods, and why they were the appropriate choice for the project. The
type of research completed utilized quantitative experimental methodology for the basic science
and descriptive analysis for the epidemiology. The two methods will be discussed separately.
Basic Science Methods
The experimental methodology focused on the basic science research question which
investigated the apparent contradiction of overexpression of hyperpolarizing channels in a cancer
cell with a membrane potential that was more depolarized. This led to the hypothesis that those
overexpressed channels were not active and could be demonstrated using electrophysiology, and
then exploited to terminate the cancer without harming normal cells. This would fill a knowledge
gap in the TNBC field where a targeted treatment is urgently needed. The methodological
approach included the tools of electrophysiology, transfection, cell cycle analysis, in-vivo mouse
modeling, and the molecular biology to evaluate resected human TNBC tumors. Experimental
studies were carefully designed with representative samples and controlled variables to allow for
the research to be reproducible by other researchers.

Methods Terminology: Techniques of Basic Science Research
Electrophysiology
The electrophysiology methods were designed to experimentally prove that the overexpressed
BK channels in TNBC were not functioning (active/open) at physiologic voltage. The resting
membrane potential for TNBC and normal breast tissue with MDA MB 231 and HMEC
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respectively is well documented and indeed TNBC is more depolarized when compared to
normal breast cells; the standard resting membrane potential for normal breast cells being ~ 60mV and resting membrane potential for TNBC more depolarized (positive) at ~ -40mV.2,3 To
evaluate if the channels were functioning whole cell patch clamp technique measured the resting
membrane potential of TNBC by breaching the cell membrane wall, then creating a giga seal to
measure its interior charge. This allowed for monitoring the voltage of the membrane potential at
rest and identifying changes when BK channel openers were added. This would give us the
overall mV of the entire cell throughout the experiment of homeostasis, BK channel opening,
drug washout, and BK channel blockade. The cells resting membrane voltages were consistent
with previous data revealing a depolarized cell at ~-40mV. To experimentally prove the BK
channels were not functioning (active/open) in this baseline recording, we then added a BK
channel specific opener. If the channels were not open (active) at baseline and forced open
(active) with this drug, then our patch clamp should demonstrate a more hyperpolarized (more
negative) membrane potential when the drug given. The results confirmed our hypothesis and the
cell demonstrated the hyperpolarized impact of 1000:1 ratio of overexpressed channels. We
repeated the test at different stimulus voltages since the cell is voltage gated and the impact was
consistent at each stimulus showing more BK channels functional (open/active) with the drug.
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Diagram 1 BK Channels Forced Open with BK Channel Opener/Activator

Treatment In-Vitro
These experiments provided a method of visual confirmation to our electrophysiologic data.
There are characteristic morphology changes in apoptosis seen with hyperpolarization due to loss
of water following the efflux of K+.4 These experiments provided time lapse video data of the
TNBC cell shrinkage with application of BK channel opener and subsequent efflux of potassium
and water. In addition, experiments utilizing ethidium red confirmed significant cell death as
fluorescent red circular apoptotic morphology replaced the original morphology of elongated
stretched cells. Finally, the control with normal healthy breast cells demonstrated no significant
death from the application of BK channel opener. These experiments were specifically designed
as molecular evidence that the impact was specific to the BK channel which was overexpressed
in TNBC and could be exploited to kill the cancer while not harming healthy cells which did not
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have the channels to respond to the drug. This specificity was a key component of the work to
provide a targeted treatment for TNBC that would not harm healthy cells.
Transfection In-Vitro (genetic mutation)
The method of transfection in-vitro provided additional experimental evidence that the
mechanism of cell death was the BK channel opening. The experiment utilized plasmid
transfection of a BK channel that was mutated to always remain open thereby mimicking the
impact of our BK channel opener. The result of the experiment was the same as the result with
cells treated by BK channel. Significant cell death produced in mutated open BK channel TNBC
but no significant cell death in wild type without mutation.
Cell Cycle Changes
Cell cycle experimental methods were designed as additional confirmation of the halt at G2
consistent with efflux of potassium from the open BK channels not allowing the cells to recover
from hyperpolarization to transition into membrane depolarization for mitosis M phase. The
experiments confirmed accumulation in G2. This method validates the hyperpolarization as
mechanism. It is well known that cells hyperpolarize in G1/S and on into G2. However, it is at
the G2/M border where cells must depolarize to begin the M phase. Our experimental methods
showed the halting at G2 where cells were unable to recover from the hyperpolarization to enter
M phase. This method design helped codify our electrophysiology data of hyperpolarization via
the BK channel as the mechanism for successful targeted treatment in experiments.
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Diagram 2: Cell Cycle Halted by BK channel Opener

In-Vivo mouse model
The design methods for the in-vivo mouse model created systematic treatment of mice by
mechanisms of tumor injection with BK channel drug to produce a treatment protocol consistent
with what could be managed in a patient population. Treatments were limited to twice a week
injections to better simulate patterns of treatment when considering logistics for translation to a
patient population. The treatment groups were compared to control groups that were not treated
with the BK channel drug. Design of methods included echocardiogram at baseline and study
completion to evaluate for impact of the drug on heart function. The method design allowed for
comparable analysis of tumor volume size between treatment and control groups to determine if
tumor growth, a measure that has clinical significance, was different between the groups. The
design not only revealed statistical significance with treatments two times a week which has
clinical application in its logistical structure, but also fostered promise for future research to
consider comparable experiments for more frequent treatments.
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Translational Human research
A first step considered in designing a method that created translational human research was the
need for the experiments to use human resected TNBC tissue, be easily reproduced, and
foundational for the work. Therefore, the logic was to use common laboratory techniques that
were feasible and had long standing histories of validation as research tools. The experimental
methods were then designed to compare human resected triple negative breast cancer tissue by
western blot and immunohistochemistry. Western blot compared human resected TNBC tissue
samples with TNBC cell lines to determine if overexpression of this BK channel was evident in
human resected TNBC tissue. Immunohistochemistry provided visual evidence of the
overexpression of the BK channel in the human resected TNBC tissue. These methods used
validated tools with ease of reproducibility to prove BK channel overexpression is a component
of the macroscopic disease of TNBC not a variant occurring due to variables such as cell line
immortalization, cell passage, or other confounders. These methods create a solid foundation to
build additional translational work.
Epidemiology Methods
The epidemiology methods utilized descriptive analysis of retrospective data from the West
Virginia breast cancer registry. A unique tool called effect measure modification was planned in
the design and methods for its benefit in identifying variables with statistical interaction. The
dataset was checked for cleanliness and missing data. Then variables were transformed to
streamlined datasets by clinical standards and analyzed.
Effect Measure modification
The method of effect measure modification evaluates an association measure, for example odds
ratio, to determine if that measure demonstrates changes over values of some other variable.5
This is an important scientific tool when deciphering epidemiologic concerns. It allows the
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research to lay a transparency, as it were, of one variable over another and determine if there is a
modification of the effect. This method exposed age at time of diagnosis as an effect measure
modification. This method is a significant tool for identifying epidemiologic issues that
otherwise would be overlooked. As an example, this research identified that women under forty
were 5 times more likely to hear their provider say they had high grade tumor at time of
diagnosis rather than low grade. With standard methodology this might get overlooked as just a
feature of aggressive cancer. However, with this method we were able to identify that a patient
seventy-one was 22 times more likely to hear her provider say she had high grade tumor at time
of diagnosis rather than low grade. Is this a delay of care issue, significant mutation of the
cancer, vulnerable population, or some other feature causing this exponential difference?
In addition, age was also an effect modifier in the multigene signature test conductance. This
method exposed the underutilization of a clinical tool in a specific, high risk population. To see
such significant exponential increase of high-risk tumor growth in a patient population receiving
less evaluation demonstrates the value of this method for identify clinical translational
opportunities to improve patient outcomes.
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CHAPTER SEVEN
Literature Review
The literature review is extensive because of the multi-disciplinary requirement of clinical
translational science. The basic science covers the relevant information regarding the BK
channel structure and function, the anatomy and physiology of MDA-MB-231 triple negative
breast cancer (TNBC), as well as TNBC as a disease, while the epidemiology component
required review of TNBC testing tools, treatment options, and how they are presently used and
available. In addition, it involved defining clinical translational science and the tool of
electrophysiology since neither are familiar to all scientists or clinicians.
BK Channel Structure
Structure of High-Conductance Calcium-Activated Potassium Channels (BK Kca) which will be
called BK throughout the rest of this manuscript is a two-unit channel with an alpha and beta
unit. The alpha unit has several N-terminus isoforms which interact differently with its beta unit.6
The alpha unit is coded for by the KCNMA1 gene.7,8 There are seven components of this
transmembrane unit, S0 – S6 with a C-terminus inside the cell, and an N-terminus external that
reaches toward the beta unit. The S0 has an extra hydrophobic segment at the NH2 terminus
followed by the S1 – S4 segment which holds the voltage sensitive domains, followed by the S5S6 pore domain.9 The internal terminus of the alpha unit called the C-terminus has four
hydrophobic segments and alternative splicing sites. There are four more regions of the Cterminus which are a stretch of negatively charged amino acids (aspartates) called the Ca2+ bowl,
a regulator conductance of potassium (RCK1). Each α-1 contributes 2 RCK. The second
regulator conductance of potassium is called the (RCK2). With each alpha contributing two RCK
they form a gating ring from the 8 RCK.9,10
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There is controversy regarding the beta subunit of the BK channel. Some research credits the
beta unit with the left shift of conductance seen with different isoforms of the channel while
others credit calcium as a modulator added to voltage rather than the structure of the beta unit.11,9
In addition to the controversy, there are four beta units coded by the KCNMB3 gene that
function as auxiliary, β1, β2, β3, and β4 to the KCNMA alpha subunit.12 Of specific interest to
clinical translational medicine is that mouse models are often used of necessity and the β3
subunit in mice shares only 62.3% amino acid identity with humans. By contrast the, β1, β2, and
β4 have a greater consistency of 83 – 95% 12 Channel complexity with alternate beta subunit
options that can modify an already variable alpha subunit reveals the need for functional
evaluation of channels.11
The pore unit of the BK channel is part of the alpha unit. It is a hemotetramer and its identical
four subunit complex demonstrates its association rather than covalent bonding between the
subunits. This region is an external part of the channel and represents the area where
tetraethylammonium (TEA), Iberiotoxin (IbTX), and Charybdotoxin (CTX) work when used as
inhibitors of the channel.13,14,9 The turret between S5 and the pore helix of the BK channel has
more residues than other potassium channels and they can reorient to impact function of the
channel.14,15
The structure of the BK channel involves recognizing many facets of the channel including
molecular weight and proteolytic decay. The alpha unit has 130 kilodalton (kDa) molecular
weight while the beta unit ranges from 20 – 30 kDa. This creates a molecular weight of 160kDa
for the complete channel without post-translational changes or proteolytic decay.16 Early
research indicates that there is discrepancy in the kDa molecular weight for the alpha unit in
different regions of the body. This discrepancy has been shown to be the product of consistent
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and reproducible proteolytic decay from its 125-130kDa full length.17,16 There are distinct
positions within the C-terminus of the alpha unit coded for by KCNMA1 where proteolysis
occurs. This creates a product with a 90kDa, 65kDa polypeptide in addition to numerous smaller
fragments such as 25kDa.17
BK Channel Function
There are many components to ion channel function. However, the one most relevant function
for this ion channel is its role in impacting resting membrane potential. Membrane potential has
three phases sometimes considered four phases; polarization, depolarization, hyperpolarization,
are the three main phases while repolarization is a return to polarization state. The BK channel
function in membrane potential is hyperpolarization. The hyperpolarization has different impacts
depending on the tissue location of the BK channel. In neurologic systems with excitable cells
the hyperpolarization can reduce firing of action potentials. In vascular tissue the BK channel
function demonstrates vascular dilation18 and in non-excitable cells the hyperpolarization
impacts resting membrane potential19, but little is understood about what that means for the cell.
This led to our query of its role and possible target potential in triple negative breast cancer
where it is overexpressed. These questions along with evidence from structure that sensitivity of
the alpha unit to shifting the mid-point activation to more hyperpolarized potentials17 regardless
of whether calcium or beta unit is the cause led to recognition of the knowledge gap.
Further literature review led to the vascular impact of the BK channel. “BKCa channels serve as
a counter-regulatory mechanism by reverting vasoconstriction, particularly in the intense
myogenic constriction of resistance vessels exposed to high intraluminal pressures.”20 This leads
to a role in cardiac function and blood pressure regulation.21
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Anatomy and Physiology of MDA MB 231 TNBC
ORIGIN
MDA MB 231 is a cell line immortalized and established in the 1970’s from an original older
cell line called BT20 which was established in the 1950’s from a pleural effusion.22 Although
this cell line was developed from a pleural effusion there is significant evidence that cell lines
maintain the transcriptional and biological heterogeneity from their primary tumors.23,24 The
value of cell lines persists even as new in vitro models with induced pluripotent stem cells
(iPSCs) develop. MDA MB 231 was not characterized as TNBC in early years due to the lack of
knowledge regarding the role of hormone receptors in breast cancer. More specific details of the
maintenance of expression pattens is noted for the MDA MB 231 cell line due to its luminalbasal TNBC subtype distinction.24 There are several cell lines utilized in the research to confirm
results were not in one cell line or subtype only. The HCC1143 cell line was used and it is Basal
A subtype also called Basal Like.25 In addition, SUM 159 cell line was used which is similar to
MDA MB 231 by subtype with both classified as Basal B or Claudin low.26 Some researchers
call Basal A and Basal B lines triple negative A and triple negative B.26 The subtyping of TNBC
can be confusing due to multiple names given to the same classification as well as continued
controversy in typing TNBC. Newest classifications are Basal-like 1, Basal-like 2,
Immunomodulatory, Mesenchymal, Mesenchymal Stem-like, and Luminal Androgen
Receptor27,28 and relate to genetic profiles for their subtype classification.
The basal-like 1 subtype has increased cell cycle and DNA damage response gene expression.29
The basal-like 2 subtype is characterized more by growth factor signaling and myoepithelial
marker enrichment.29 The immunomodulatory(IM) subtype, as expected is characterized by
enrichment of genes encoding for immune function such as those for immune antigens,
cytokines, and core immune transduction signals. There is significant evidence that this is from
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both the tumor and infiltrating lymphocytes. The IM subtype has the largest lymphocyte
percentage at 38%.29,30 Mesenchymal has the lowest at 9% while basal-like 2 comes in at 23%
followed by mesenchymal stem-like at 21%, luminal androgen receptor at 17%, and basal-like 1
at 15%.29
As expected, mesenchymal and mesenchymal stem-like share similarities with elevated
expression of growth factor pathways. However, mesenchymal stem-like shows decreased
expression of genes involved in proliferation. 29
Luminal androgen receptor subtype is characterized by luminal gene expression and is
predominantly propelled by the androgen receptor.29
The scientific and clinical communities have struggled to classify the subtypes of TNBC because
of these genetic variations that are overlaid with relapse-free survival differences, metastatic
differences, histological variation, and response to therapy variation. For example, basal-like 1
demonstrates higher grade, lower stage with increased likelihood of complete response to
treatment, as well as overall increased relapse free survival. Luminal androgen receptor tumors
demonstrate increased regional spread, their distant metastases is inclined to bone, and their
histology, which is commonly lobular carcinoma, is exclusive to this particular subtype of
TNBC.29
Mesenchymal tumors are predisposed to metastasize to lung. Their histology is metaplastic
carcinoma similar to basal-like 2, yet again is different in other capacities to warrant a separate
classification of the two.29
Metabolic variation based on phosphorylation profile raised some additional molecular
characterization points of consideration for classification.31,32,33,34

MORPHOLOGY
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The morphology of the MDA MB 231 cell line we used demonstrated consistent morphology in
media-based incubation. The characteristic morphology of MDA MB 231 has a 200-600µm2
spreading area35 in gel based culture. The cells elongate along arbitrary lines.36 These
characteristics were helpful in utilization of the cells for patch clamp. The stretch allowed for
examination of the cell under the microscope light to evaluate by shadow lines for the best point
for an electrophysiology patch. In addition, the specific stretch and elongation pattern of the cell
made the evidence of shrinkage and rounding, during treatment, as an early sign of apoptosis
significantly evident.
MEMBRANE POTENTIAL
Membrane potential at the cellular level is key to this research. The electrophysiology, which is
the electrical function of a normal biological organism, identifies why the overexpressed BK ion
channel is not functional at physiologic voltages, and can be a potential target against TNBC.
To discuss membrane potential, it is necessary to discuss how cells mimic an electrical circuit.

Diagram 3: How Cells Mimic Electrical Circuits
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Diagram 4: Understanding Voltage and Membrane Potential
Electrical charge +/ – moves from inside to outside the cell or vice-versa and creates the
difference which we measure as voltage.

Terms:
Coulombs – The coulomb is the standard unit of electric charge. Electrons are too small to be
used as the measure of electric charge. Therefore, we identify a collection of them as an electric
charge. That collection is defined as the number of electrons that can pass through a set point in
one second. The number of electrons that can do that is 6.24 x 1018 electrons or one coulomb.
Ampere – The ampere is the unit of electric current and is expressed as the flow of one coulomb
(6.24 x 1018 electrons) per second. Therefore, 1 ampere (amp) = 1 coulomb per second.
In electrophysiology patch clamp measurements are in picoamps (1 picoamp = 1 x 10-12 amp).
Voltage – The force of potential difference. One volt is one joule of energy (work done by the
force of that potential difference) per coulomb. The cell membrane potential is measured in mV
in whole cell patch clamp. Therefore, we can measure the force of potential difference across
that cell membrane and identify its quantitative number in mV. These mV represent the cell
potential for work (ie…joules of energy as volts). This concept is easiest to understand in a cell if
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discussed first as an action potential in a cell then discussed in regards to changes in resting
potential. The Hodgkin cycle described in the original work of 1952 conveys the idea well. The
opening of sodium (Na) channels moves the cell towards depolarization (more positive) by
moving Na into the cell. Then as the potassium (K) channels open K moves out of the cell
causing hyperpolarization (more negative) membrane potential before returning to the
physiologic or normal resting membrane potential.37

Diagram 5: Membrane Potential: From Threshold to Hyperpolarization

The importance of this in relation to the TNBC work is the electrophysiologic evidence that
TNBC has a resting membrane potential that is more depolarized (more positive) than normal
breast cells. This increased depolarization is associated with increased proliferation which is
rapid reproduction of cells commonly seen in cancers.4
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Diagram 6: Resting Membrane potential TNBC vs Normal Cells

Our research confirmed this increased depolarization of the resting membrane potential of TNBC
compared to normal breast cells. In addition, our novel discovery that the overexpressed BK
channel in TNBC was not functioning (active) at physiologic voltage led to our hypothesis that
the overexpression of the hyperpolarizing BK channel was not impacting the cell; and this could
pose an opportunity to activate those channels and severely hyperpolarize and thereby kill the
TNBC cells by efflux of potassium.

TNBC the Disease
TNBC is a devastating disease with a lower five-year survival rate, increased risk for recurrence,
and highest rate for brain metastases of all breast cancers.38,39,40,41 TNBC is estrogen,
progesterone, and human epidermal growth factor receptor (HER2) negative. This creates a
significant challenge for oncologists owing to the recurrence and metastasis which result in a
poor prognosis.42
TNBC Treatment Options
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Chemotherapy
Knowledge about cancer treatment for TNBC is still maturing. TNBCs are transcriptionally
heterogeneous and can be grouped into subtypes with vastly differing biology and responses to
chemotherapy and targeted therapies.43 Later research by Lehmann discusses the identified
TNBC cell lines representative of each subtype and demonstrated differential sensitivity to
alkylating agent cisplatin29 which raises new purpose for some of the testing discussed in the
epidemiology project. These are treatment variations that were unknown several years ago.
“In a prior retrospective analysis of patient pretreatment biopsies, TNBC type molecular
subtypes were predictive of response to neoadjuvant anthracycline and cyclophosphamide
followed by taxane (ACT), with BL1 subtype tumors exhibitng the highest pCR (52%) and BL2
and LAR subtypes the lowest (0 and 10%, respectively). These results suggest that certain TNBC
subtypes are intrinsically sensitive or insensitive to neoadjuvant chemotherapy.”29
Conventional therapies employed in treatment of TNBC suffer from issues of poor
bioavailability, poor cellular uptake, resistance, and undesirable off-site toxicities.42
Surgery
Surgical resection is standard care for all breast cancer. However, the decision for lumpectomy
versus mastectomy often discussed with estrogen positive breast cancer patients and others is not
a similar discussion with patients diagnosed with triple negative breast cancer. Although early
literature up through around 2010 discusses breast conserving surgery as an option in TNBC, it is
not as commonly seen after 2010 accept with adjuvant radiation therapy.44,45 The topic is
controversial and many clinicians continue to recommend full mastectomy. The aggressive
nature, heterogeneity, and lack of treatment options increasingly leads to mastectomy as only
surgical option. Here again the increased use of clinical tests such as the improved multi-gene
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signature test could afford us valuable information about this difficult disease allowing us to
create better options for care via the data produced to basic science for discovery of biomarkers,
and treatment targets.
Radiation
Radiation therapy has found an increasing role in TNBC treatments with research projects that
demonstrated improved five year survival and disease free rates in patients receiving radiation as
neoadjuvant therapy.45,46 It is increasingly evident that radiation as neoadjuvant therapy is
beneficial in TNBC patients receiving either breast conservative therapy or mastectomy and it is
the molecular information regarding the biological characterization of subtypes that are
improving clinician decision making for neoadjuvant therapy.46 These principles once again
support the evidence of the epidemiology study that improved utilization of molecular testing
such as multigene signature tests could dramatically change the landscape of treatment options
and decision making in TNBC by generating the data that assists in subtyping TNBC, and
identifying basic science research targets for neoadjuvant treatment in this aggressive disease.

Breast Cancer Testing
Breast cancer testing is documented across the United States by established protocols from
Surveillance, Epidemiology, and End Results (SEER). SEER started in five states in 1973 and
now has expanded across the United States.47 West Virginia is one of the last remaining states
that do not report their data to SEER. However, the West Virginia cancer registry is set up based
on the SEER protocols. The site specific cofactors listed below are from the West Virginia
registry and have been placed in a table format with appropriate links for details regarding their
definitions and coding.
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Breast Cancer Testing (CS Site Specific Co-factors from WV Cancer Registry and Seer)

CS site specific Cofactor #
1
2

3

4
5
6
7

8

9

10

11

12

13
14
15
16

Title

Coding Link
http://web2.facs.org/cstage0205/breast/Brea
Estrogen Receptor Assay st_jag.html
Progesterone Receptor http://web2.facs.org/cstage0205/breast/Brea
Assay
st_kac.html
Number of positive
ipsilateral level I-II
http://web2.facs.org/cstage0205/breast/Brea
Axillary Lymph Nodes st_lac.html
Immunohistochemistry
of Regional Lymph
http://web2.facs.org/cstage0205/breast/Brea
Nodes
st_mab.html
Molecular studies of
http://web2.facs.org/cstage0205/breast/Brea
Regional Lymph Nodes st_naa.html
Size of Tumor Invasive http://web2.facs.org/cstage0205/breast/Brea
Component
st_oaa.html
Nottingham/Bloom
http://web2.facs.org/cstage0205/breast/Brea
Richardson Score/Grade st_saa.html
HER2
Immunohistochemistry http://web2.facs.org/cstage0205/breast/Brea
Lab Value
st_sab.html
HER2:
Immunohistochemistry http://web2.facs.org/cstage0205/breast/Brea
Test Interpretation
st_sac.html
HER2 Fluorescence in
Situ Hybridization (FISH) http://web2.facs.org/cstage0205/breast/Brea
Lab Value
st_sad.html
HER2 Fluorescence in
Situ Hybridization (FISH)
Test Interpretation
HER2: Chromogenic In
situ Hybridization (CISH)
Lab Value
HER2 Chromogenic In
situ Hybridization (CISH)
Test Interpretation
Result of Other or
Unknown Test
HER2 Summary Result of
Testing
Combinations of ER, PR,
& HER2 Results

http://web2.facs.org/cstage0205/breast/Brea
st_sae.html
http://web2.facs.org/cstage0205/breast/Brea
st_saf.html

http://web2.facs.org/cstage0205/breast/Brea
st_sag.html
http://web2.facs.org/cstage0205/breast/Brea
st_sbf.html
http://web2.facs.org/cstage0205/breast/Brea
st_sbg.html
http://web2.facs.org/cstage0205/breast/Brea
st_sah.html
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14

Unknown Test
st_sbf.html
HER2 Summary Result of http://web2.facs.org/cstage0205/breast/Brea
15
Testing
st_sbg.html
Combinations of ER, PR, http://web2.facs.org/cstage0205/breast/Brea
Breast Cancer
Testing
(CS
Site
Specific Co-factors
from WV Cancer Registry and Seer) Continued
16
& HER2
Results
st_sah.html
Circulating Tumor Cells
and Method of
http://web2.facs.org/cstage0205/breast/Brea
17
Detection
st_sai.html
Disseminated Tumor
Cells and Method of
http://web2.facs.org/cstage0205/breast/Brea
18
Detection
st_saj.html
Assessment of Positive
Ipsilateral Axillary
http://web2.facs.org/cstage0205/breast/Brea
19
Lymph Nodes
st_sak.html
Assessment of Positive http://web2.facs.org/cstage0205/breast/Brea
20
Distant Metastases
st_sal.html
Response to
http://web2.facs.org/cstage0205/breast/Brea
21
Neoadjuvant Therapy st_sam.html
Multigene Signature
http://web2.facs.org/cstage0205/breast/Brea
22
Method
st_san.html
Multigene Signature
http://web2.facs.org/cstage0205/breast/Brea
23
Test
st_sao.html
http://web2.facs.org/cstage0205/breast/Brea
24
Paget Disease
st_sap.html
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CHAPTER EIGHT
Figures and Tables
Temporal Lobe Epilepsy, Stroke, and Traumatic Brain Injury: Mechanisms of
Hyperpolarized, Depolarized, and Flow-Through Ion Channels Utilized as Tri-Coordinate
Biomarkers of Electrophysiologic Dysfunction

Figure 1 The casting of the entire vascular network 1A in a 24-month old male wild type mouse.
The cast created with polyurethane resin and image acquired with micro CT system for
visualization of collateral vasculature structure (Picture courtesy of Dominic Quintana,
Neuroscience Department, West Virginia University). In 1B Computed Tomography
Angiography of the normal single side internal carotid end artery system in human. The internal
carotid artery supplies the anterior circulation to the brain and includes the middle cerebral artery
(MCA) commonly associated with stroke and the anterior choroidal artery, which is a feeding
vessel, from the anterior system, the hippocampal region associated with the sclerosis of
temporal lobe epilepsy. In 1C the anterior choroidal artery in humans is the only artery branch
feeding the hippocampus from the anterior system, apart from the recurrent artery of heubner.
The mouse has a more collateral reach to the hippocampus possibly contributing some
neuroprotection during injury.
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Figure 2 The glass pipette as electrode 2A in the recording bath where the astrocyte 2B is
adhered to the coverslip. 2C demonstrates the patch between the electrode and the astrocyte
under the microscope. Finally, 2D is an example of real time electrical current received from a
cell.

Figure 3 In 3A the variability of the pyramidal cells is shown by the CA1 and CA3 pyramidal
neurons compared to the Layer V (LV) pyramidal neuron when you look at where and how the
branching occurs. The LV pyramidal neuron has a streamline look and reaches through all six
layers of the neocortex 3B while the more compact CA1 and CA3 of the hippocampus with their
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apical branching are designed for their local purpose. In 3C the arrows indicate the location of
the soma where patch clamp recording gives the reading of the resting membrane potential of the
entire cell. Picture reprinted by permission from Macmillan Publishers Ltd: [Nature Reviews
Neuroscience] [21], copyright (2008). Finally, in 3D, the ramp protocol, and 3E, the pulse
protocol, you see examples of recordings received from a cell with two different protocols in the
whole cell patch technique. Protocol examples are from our research lab at West Virginia
University.

Figure 4 Nernst equation calculation for Chloride demonstrates the electrophysiologic alteration
of membrane potential possible with fluctuations of Cl− in conditions such as ratio shift of
NKCC1 to KCC2. Their correct ratio is necessary for neutrality of charge. Repeat the calculation
on your own by changing the outside and inside molarity to demonstrate what can happen if the
ratios of expression for these channels are not appropriate.
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Table 1 The voltage measurements from Della Santina [44] in their work with HCN1 channels
in the retina converted to a table to demonstrate the value of monitoring Ih current of the HCN1
channel. The results indicate the channel in response to hyperpolarization and depolarization and
indicate the potential for biomarker mechanism in the electrophysiologic function of neurologic
disease.
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Opening Large-Conductance Potassium Channels Selectively Induced Cell Death of TripleNegative Breast Cancer

Figure 1 KCNMA1 gene expression in five molecular subtypes of breast cancer. Each dot
represents one patient. Gene expression levels are presented as FPKM in log2 expression. Red dots
are basal-like triple-negative (TN) breast cancer patients. Blue dotted line indicates KCNMA1
gene expression in normal breast cells. FPKM: Fragments Per Kilobase of transcript per Million.
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Figure 2 Protein expression of BK channel -subunit (forming the functional channel) in
TNBC cells and patient tissues. (A) Western blots with antibody, M: marker, MDA231: MDAMB-231 cells (cell positive control), Normal: normal primary breast tissue, TNBC: TNBC patient
tissue, MB: mouse brain (tissue positive control). -actin was used as a loading control. (B)
Western blots with antibody and antigen, confirming signals detected by the antibody in (A). (B)
Quantitative expression levels of BK channel proteins normalized to -actin (n=4-6). Unpaired t
test was performed. Two-tailed p=0.0002, t=0.8172. (D) Western blots using a BK channel protein
antibody in MDA231, SUM159, MCF10A, and HCC1143, b-actin as loading controls.
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Figure 3 Biophysical properties of BK channels in MDA-MB-231 cells. (A) BK channel
currents elicited by depolarizing pulses ranging from -40mV to +50mV in 10mV increment,
pulse protocol is shown below. (B) BK channel conductance, G, – voltage relationship in the
absence (black) and presence (red) of 0.1 M IbTX (n=8). (C) Effects of BMS-191011 and IbTX
on membrane potential (Em) in MDA-MB-231.
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Figure 4 BK channel openers induced cell death in TNBC cell lines. (A) BMS-191011 (20
M) induced cell death on normal breast cells (MCF10A, dark), ER+ breast cancer cells (MCF7,
grey), and TNBC cells (MDA-MB-231, red) (n=5). One-way ANOVA was performed,
p<0.0001, F=65.38. (B) Time- and concentration-dependent effects of NS11021 on growth of
MDA-MB-231 cells (n=6). Two-way ANOVA was performed, p<0.0001, F=66.67, DF=9. (B)
Time-dependent effect of BMS-191011 (20 M) on growth of SUM159 cells (n=4). Two-way
ANOVA was performed, p<0.0001, F=618.9, DF=6. (D) Time-dependent effect of BMS-191011
(20 M) on HCC1143 cells (n=4). Two-way ANOVA was performed, p<0.0001, F=27.6, DF=4.

86

Figure 5 BMS-191011 induced activation of caspase-3 in MDA-MB-231. Using caspase-3/7
green dye, fluorescence was detected after incubation of 10 M BMS-191011 for three days (B).
Light image is shown in (A). Scale bar: 20m. Using immunoblots, caspase-3 was detected in
three TNBC cell lines (MDA-MB-231, HCC1143, SUM159) (C). Cleaved caspase-3 was
detected after BMS-191011 treatment (D, M-marker, red arrow indicates pro-caspase 3, black
arrow indicates cleaved active caspase 3).

Figure 6 BMS-191011 induced arrest in S/G2 phases of MDA-MB-231. (A): No treatment
(control), (B): Drug treatment for 24h, (C): Drug treatment for 48h. Blue: G1 phase; Green: S
phase; Red: G2 phase. Count: amount of cells, PI-A: fluorescence intensity.
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Figure 7 Slowing of MDA-MB-231 xenograft tumor by BK channel opener. (A): Three
paired-tumors of similar sizes (C1/T1, C2/T2, C3/T3) are shown to illustrate the inhibitory
effects of BMS-191011 in tumor growth. Ultrasound imaging was performed once a week to
calculate the tumor volume (mm3) for four weeks. A reconstruction of the tumor volume from
ultrasound imaging is shown in the inset. (B): Average tumor volume in control (n=8) and
treated groups (n=8). *: p<0.05 (t-Test was performed, two-tailed p=0.0356, t=2.32592).
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SUPPLEMENTAL FIGURES
Supplemental Fig. 1

Supplemental Fig. 1 Immunohistochemistry of BK channels in TNBC patient
tissues (IHC). (a) normal breast tissue, (b) TNBC tissue (BK channel expression
indicated by brown color, see Methods), (c) Percentage of staining area averaged from
seven TNBC and three normal breast tissues. Unpaired t-test was performed, two-tailed
p=0.0042, t=3.95.

Supplemental Fig. 2

Supplemental Fig. 2 BMS-191011 on human breast cancer cell lines. Upper
panels show the bright-field images, lower panels show the dead cells labelled by EthD1 dye (red). BMS-191011 (20 M) treatment of MCF10A (left), MDA-MB-231 (middle),
and MCF7 (right) after 2 days. Scale bar: 20 m.
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Supplemental Fig. 3

Supplemental Fig. 3 Concentration-dependent effects of NS11021 on MDA-MB231 after 5 days. Upper panels show the effects of NS11021 in bright field, lower
panels show the dead cells labelled by EthD-1 dye (red). Scale bar: 20 m.

Supplemental Fig. 4
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Supplemental Fig. 4 Concentration-dependent effects of BMS-191011 on
SUM159 after 5 days. Upper panels show the bright-field images, lower panels show
the dead cells labelled by EthD-1 dye (red). Scale bar: 20 m.

Supplemental Fig. 5

Supplemental Fig. 5 BMS-191011 on HCC1143. Upper panels show the effects of
BMS-191011, lower panels show the dead cells labelled by EthD-1 dye (red). Left:
control; Right: one day after 10 M BMS-191011 treatment. Scale bar: 20 m.

Supplemental Fig. 6
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Supplemental Fig. 6 DMSO on HCC1143. DMSO (5 l, corresponding to the
volume used for 50 M BMS-191011) on HCC1143. Upper: after 48hr; Lower: after 96hr.
Left: light image, Right: dead cells labelled by EthD-1 dye (red). Scale bar: 20 m.

Supplemental Fig. 7
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Supplemental Fig. 7 MDA-MB-231 cell death induced by a constitutively open
BK channel mutant, A313D. WT: wild-type BK channel, A313D: mutant channel, GFP:
GFP plasmid, *: p&lt;0.05.

Supplemental Fig. 8

Supplemental Fig. 8 Three images corresponding to starting time point (control, t=0) (A),
20min (B), and 60min (C) after BMS-191011 (1 M) application are shown. Red arrows
illustrate the representative cells undergoing morphological changes during the time
course of BMS-191011.

Supplemental Fig. 9
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Supplemental Fig. 9 Prevention of MDA-MB-231 cells migration by BMS191011. In the absence of BK channel opener (Con) (A), cells migrated to fill the gap
(“wound”) after 4hrs (B). Low concentration (100nM) of BK-191011 (C) prevented the
“heal” (cells filling the gap) after 4hrs (D). Scratch is defined by the space within two red
lines. Curved red line indicates the marker (shadowed area) used to identify the location
of the scratch. Scale bar: 20 m.

Supplemental Fig. 10
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Supplemental Fig. 10 DMSO does not affect cell cycle in MDA-MB-231. a: no
DMSO treatment, b: DMSO treatment after 24h. Blue: G1 phase; Green: S phase; Red:
G2 phase. Count: amount of cells, PI-A: fluorescence intensity.

Supplemental Fig. 11

Supplemental Fig. 11 BK channel opener does not alter cardiac functions in
NSG xenograft model. Results of three control and four treated mice were compared. C: control,
T: BMS-191011 treated. HR: heart rate (beat per minute, BMP), EF: ejection fraction (%), LV:
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corrected left ventricular mass (mg), CO: cardiac output (mL/min). Unpaired t-Test was
performed. For HR, p=0.6621, t=0.4595; For EF, p=0.5281, t=0.6695; For LV, p=0.5209,
t=0.6816; For CO, p=0.9443, t=0.07285.

Supplemental Fig. 12

Supplemental Fig. 12 Supplemental Figure 13: BK channel opener induced cell death in MDAMB-231, but not in cardiac myocytes. A: MDA-MB-231 stable cell line with DsRed inserted. B:
H9c2 cardiac myocytes. C: co-culture of MDA-MB-231/DsRed cells (red) with H9c2
cardiac myocytes (gray) after one-day treatment of BMS-191011 (20 M). D: co-culture
of MDA-MB-231/DsRed cells (red) with H9c2 cardiac myocytes (gray) after six-day
treatment of BMS-191011 (20 M). Scale bar: 30 m.
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Triple Negative Breast Cancer: Exponential Tumor Grade Increase with Age of Diagnosis
Table 1
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Table 1 Continued
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CHAPTER NINE
Conclusion
This composition of three projects reflects the perspective of clinical translational science. The
first work reviews the use of electrophysiology in the microscopic and macroscopic world,
demonstrates a novel means of connecting them with this tool, and discusses opportunities for
future research on a broad scale. The second work tackles application of electrophysiology to
identify a novel targeted treatment for an aggressive breast cancer disease, triple negative breast
cancer. Finally, the electrophysiology discovery guides the hypothesis for an epidemiology study
to determine the use of molecular signature testing for triple negative breast cancer in the West
Virginia population to prepare the way for future research identifying biomarkers and targets for
this disease.
Electrophysiology in Clinical Translational Science creates novel opportunity for translating
basic science to the clinic by virtue of a tool that communicates data across the chasm between
the microscopic scale of bench science and the macroscopic scale of clinical application. This
tool creates novel application of electrophysiology for disease evaluation across measures of
scale. It provides functional evaluation of genetic data regarding over-expressed and underexpressed ion channels to guide discovery for disease treatment. Finally, it advances
epidemiologic discovery by generation of novel insight for researching disease in the population.
Utilizing electrophysiology to bridge the gap between microscopic basic science discovery and
macroscopic clinical application is a difficult challenge. This project seeks to recommend growth
in the use of electrophysiology beyond the boundaries of this work, demonstrate the novel use of
it in development of targeted treatment for a disease, and exhibit its novel provision to
epidemiologic guidance of disease research in the population.
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In addition, the ability of electrophysiology in ion channel evaluation to resolve a significant
contradiction in the literature of BK ion channels demonstrates its formidable ability to give
functional quantitative answers to the ambiguity of genetic expression. Prior to this research
controversial results of the BK channel in breast cancer proliferation and treatment were blatant.
Khaitan et al in his 2009 work demonstrated that metastatic brain cancer from breast
overexpressed BK channels more than metastatic cancer from the breast to other organs. From
this he concluded that the migration and invasion was due to the increase of BK channel and that
blocking the channel would be an effective way to impact this process.48 However, what was
overlooked is the function of the channel. Our research has demonstrated that the BK channel is
not open (active) at physiologic voltage therefore inhibition of a closed channel is unlikely to
produce the impact anticipated.
Indeed, research by additional scientist have demonstrated that inhibition did not have the
anticipated impact. Schickling’s discussion in Oncogene Report regarding their equivocal results
caused him to note that BK channels may be pro or against growth.49 The significant contribution
of this dissertation to facilitate a final answer to this controversy not only gives perspective to the
cause of the contradictions (ie…not evaluating channel function) but also provides solid,
reproducible techniques for future ion channel research in diseases with over and under
expressed ion channels.
Finally, the in vitro altered homeostasis in ion channel targeting of a single cell of human triple
negative breast cancer and the in vivo impact of its application in mice can be discussed with
clinicians using the language of electrophysiology regarding polarization, depolarization, and
hyperpolarization, a language they already speak with EKG analysis in their daily routines. It is
this hyperpolarization which is the mechanism of cell death when the overexpressed BK
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channels are forced open and potassium efflux leads to apoptosis. The evidence for potassium
efflux as mechanism for apoptosis is well demonstrated.50 Our research utilizing
electrophysiology demonstrates hyperpolarization to confirm potassium efflux via the BK
channel as mechanism of apoptosis in triple negative breast cancer. Therefore, this genetic
variation of overexpression can be exploited to target the disease. Electrophysiology gives
functional answers to the decades of accumulated genetic research. Patch clamp, as an
electrophysiology tool speaks in the physics language of electrical current which translates from
basic science to the clinic.
The language barrier electrophysiology bridges between basic science and clinical medicine
offers a significant opportunity to utilize a tool that will give functional data to our growing
collection of genetic data that can be translated to clinical application. The initial manuscript in
this dissertation work discussed interconnected evaluations of multiple ions and ion channels that
is still very difficult to do and will require extensive modeling to fully develop. However, the
second manuscript in this dissertation demonstrates a beginning step in that direction by utilizing
a transmembrane channel that operates by interaction with two ions; the ion transported across
the membrane -potassium - and the ion that impacts its gating, calcium. The evidence of the BK
channel to selectively kill triple negative breast cancer in-vitro and halt tumor growth in-vivo is a
novel discovery for targeted treatment of triple negative breast cancer with BK channel openers
that addresses the contradiction of previous research which only considered its overexpression
not its electrophysiologic activity at physiologic states. This new evidence demonstrates BK
channel opportunity as a targeted treatment and confirms the role of calcium in proliferation
rather than the BK channel which is simply impacted by the increased calcium. Finally, the third
manuscript provides evidence for decreased utilization of tests, such as the multigene signature
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test, which can identify molecular biology variants like overexpression, and response to
treatment. Together these create an opportunity for explosive translational growth as we wield
these discoveries into additional research and change.
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APPENDIX A
Clinical Translational Science Definition and Purpose
The definition and purpose of Clinical Translational Science is still evolving. As any new
science field, the parameters are set and then adjusted as the field matures. There are five phases
of translational research defined by the clinical and translational scientific community (T0-T4).51
Translational research is a multi-directional process which integrates multidisciplined science
across populations, basic science, policy, and clinical application.52 The National Center for
Advancing Translational Science speaks of the developing nature of clinical translational
science. “At all stages of the spectrum, NCATS develops new approaches, demonstrates their
usefulness and disseminates the findings. Patient involvement is a critical feature of all stages in
translation.”53 The long-term goal of this project is to advance clinical and translational science
by demonstrating electrophysiology utilizes a language of physics which speaks fluently from
the microscopic to the macroscopic, reaching from the atomic to the cosmic to address human
questions in basic science, and clinical medicine.. The initial discussion and first publication
address the complexity of the problem translational science faces and the opportunity
electrophysiology creates to generate mechanisms for evaluation. The broad scale is then
narrowed to illustrate this principle through the second paper which encompasses the basic
science research, pre-clinical research, and the clinical research by cell line in-vitro work,
xenograft mouse model work, and human resected cancer tumor work respectively; this gives
evidence for the functional role of BK (big conductance potassium) channels for targeted
treatment in triple negative breast cancer (TNBC). The third discussion continues the precedent
for research translation from basic science to clinical practice by epidemiology research to
evaluate TNBC in our local patient population of West Virginia utilizing the West Virginia
Cancer Registry. Finally, the conclusion outlines the future research which extends beyond this
111

reference to generate the collaborative radiation neoadjuvant treatment with targeted ion
channels in mice, followed by randomized clinical trials targeting BK ion channels as
neoadjuvant treatment with radiation prior to tumor resection in patients with TNBC. In
accordance with the goals of the NIH National Center for Advancing Translational Science this
research aims to harmonize the diverse measures of scale between molecular biology and clinical
medicine. This project completes both T0, T1, and T4 research with defined direction for future
research in phases T2 for clinical application.
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